Podcasts about Necco

Love 'em or hate 'em, we know you hate 'em. This week we're getting both retro and divisive with the classic Necco Wafers.  Get ready for the history of Necco Wafers. Get ready for a review of Necco Wafers. Get ready to hate what you hear. Grab a tube and eat along with us if you dare!

Shoot us a Text.Happy Super Bowl parade day, Eagles fans! Happy Valentine's Day to the rest of you! Today, we're breaking down how Chinese OEMs are able to build lower cost vehicles with more speed than traditional OEMs. Plus, we look at Toyota's plans for more inventory in 2025 and a history of Valentine's Day candy.Show Notes with links:A teardown analysis by Caresoft Global Technologies reveals that Chinese automakers are rapidly surpassing the Detroit 3 in cost efficiency, speed, and innovation. While legacy automakers struggle with outdated manufacturing methods, Chinese brands are cutting costs, streamlining production, and expanding aggressively into global markets.Detroit automakers use 12 rare-earth magnets and steel brackets to secure headliners, while Chinese automakers achieve the same result with inexpensive adhesive strips; similarly, Detroit 3 EVs rely on costly aluminum braces, whereas Chinese EVs use lighter, more affordable plastic or thin metal brackets.Meetings with Chinese automakers take one week compared to two months with German OEMs and nine months for a purchase order from a legacy automaker.At a Caresoft presentation in China, 700 employees showed up on a Saturday—a level of commitment rarely seen in the U.S.Toyota is pushing for increased production and sales in 2025 after a strong 2024, despite supply chain hurdles and stop-sales. The company saw record accessory sales, nearly record parts sales, and a 3% increase in U.S. light-vehicle sales, totaling 1.99 million units.Toyota built over 2 million vehicles in North America in 2024 and plans to increase output in 2025 to improve inventory levels.Toyota dealers have adapted to a lean inventory, high-throughput model, preselling vehicles and managing allocations efficiently.Hybrids and plug-in hybrids made up 43% of U.S. sales in 2024, up from 29% in 2023. Toyota expects 50%+ in 2025, rising to 60-70% long-term as its North Carolina battery plant boosts hybrid production.After weather disruptions at the NADA Show in January, Toyota executives and retailers met virtually this month, where brand head Dave Christ emphasized the company's focus for the year: “Our message [for 2025] is very simple: It's build more and sell more.”Valentine's Day remains a battle between flowers and candy, with 56% of celebrants purchasing candy and 40% buying flowers in 2024. Despite candy's popularity, flower sales ($2.9B) edged out candy sales ($2.5B). Over the years, candy brands have introduced creative and sometimes bizarre Valentine's treats.Here are some key moments in Valentine's Candy History:1868: Cadbury debuts the first heart-shaped candy box.1902: Necco produces its first conversation hearts with sayings like “Be Mine.”2019: Smarties Candy Co adds the sayings “Swipe Right,” “Text Me,” and “YOLO” to their conversation hearts2024: Protein-packed “Meathearts” beef jerky is introduced. Printed sayings include “Meat Me” and “Beef MineHosts: Paul J Daly and Kyle MountsierGet the Daily Push Back email at https://www.asotu.com/ JOIN the conversation on LinkedIn at: https://www.linkedin.com/company/asotu/ Read our most recent email at: https://www.asotu.com/media/push-back-email

The sisters share secrets and stories about Valentines Day, Galentines Day, and their must-see rom comsThey also invite their husbands on for a round of the Not So Newlywed Game. Do the fishes know their husbands?https://www.history.com/topics/valentines-day/history-of-valentines-day-2What's for dinnerhttps://www.foodnetwork.com/recipes/ina-garten/steakhouse-steaks-recipe2-1923191https://www.foodnetwork.com/recipes/ina-garten/baked-potatoes-recipe-1925507https://www.foodnetwork.com/recipes/ina-garten/caesar-salad-with-parmesan-croutons-13126808

Within Brims Skin. Man On the Run #281. -- The gang is at it again. Brimstone is joined by his wing-man Alex DaPonte and his wife Danielle as they chat about the worst Halloween candy, how Necco Wafers are way worse than Candy Corn, why Circus Peanuts are even a thing and why it's good to have friends with different flavor profiles. They discuss the Halloween plans or lack thereof, ball shaving, Alex's love for burnt popcorn and how pickle juice drinking is actually a thing. They discuss the rancid tales of an Uber puker, and more pickle conversation. Brim explains what gets Within Brim's Skin.

In this episode, we're learning all about the incredible history of candy manufacturing in Boston. With Jeremy Spindler of Spindler Confections as our guide, we cover the meteoric rise and slow demise of a signature New England industry — it's a bittersweet tale, to say the least. And as a bonus, it's taste test time! Listen as I sample some of the area's classic candies, including the famous/infamous Necco wafers. Let's just say that times — and tastes — have changed.Here's video of the Gloucester Greasy Pole and info on the upcoming St. Peter's Fiesta (June 16-30).  Have feedback on this episode or ideas for upcoming topics? DM me on Instagram, email me, or send me a voice memo.If you're a local business who'd like to advertise on the podcast, please drop me a line.For merch, head to Explainbostontome.com.Send us a Text Message.The Outback Summer Program at the Maria L. Baldwin Community Center is a high-quality summer camp for rising K through 6th graders who value creativity, culture, and community. Outback currently has openings throughout the summer. Interested in enrolling? Learn more at agassiz.org or by contacting registration@agassiz.org . Premium Q Moving & Storage: Get free boxes and 10% off your move by clicking HERE or call 781-730-6180 for a quote.

In a wide-ranging interview with WHAV this week, Haverhill Mayor Melinda E. Barrett took listeners behind the scenes on recent moves affecting the futures of both the “big” and “little” Whittier schools.Barrett, in her fourth month working out of the corner office at City Hall, took some time Wednesday to appear on WHAV's “Win for Breakfast” program. The mayor said she spoke with Gov. Maura T. Healey recently as plans took shape to explore a shared campus for Whittier Regional Vocational Technical High School and Northern Essex Community College.“So, the idea would be to build a Whittier Vo-Tech and align it with NECCO so they could capture some different dollars rather than just the 11 communities relying on (Massachusetts School Building Authority) and their own tax levy capacities. This would open up even more grant opportunities, some federal funding, take advantage of job training monies that might be out there from both the state and federal government to try to reduce the cost to the communities and produce a school that will produce workers for the future,” she said.During January's vote of Whittier Tech communities, only Haverhill supported plans for a $445 million replacement school.As WHAV reported first, Barrett recently met with other communities and made clear the city's opposition to reopening the 1967 Whittier Tech agreement.“I don't know the motivation behind the other communities as far as how they feel. We had a meeting last week with all 11 communities and many of them want to open up the charter and basically shift the cost burden to Haverhill more than it already is. I told them I would not approve opening the charter due to that fact.  I won't vote for that. When I did tell them that, one of the town managers from a different community said ‘Of course you wouldn't. If I were in your shoes I wouldn't either.'”The mayor also related the backstory about how the John C. Tilton School came to be considered as part of the replacement of the John Greenleaf Whittier School on Concord Street.“When they came to tour, I guess last year at some point, they toured the J. G. Whittier and they also looked at the Tilton. Initially, we only put in for the J. G. Whittier, and they let us know that if we wanted to consider a combined school, similar to what (Caleb Dustin) Hunking is, that we would have to put in a statement of interest for Tilton also, so that they could, in their concept, consider doing a combined school. Without our application for Tilton, they would not have considered it,” Barrett explained.She said the J.G. Whittier middle school application has already been accepted by the state, but she doesn't have a timeline for the Tilton application.The mayor also previewed a lead hazard reduction grant the city received which she called, a “whopper.” It will, in part, benefit families in older housing.Support the show

Hello Backstory fans! Join us for an exciting episode, as we delve into the love story of country music artists, Bobby Tomberlin and Tess Frizzell, who discuss their respective musical journeys filled with shared experiences, challenges, triumphs, and how their paths crossed in Nashville. Amid their professional struggles, they highlight the importance of mutual respect, authenticity, and the transformative power of shared experiences in deepening their bond. The story unfolds further, taking us on an intimate journey through their career milestones, hilarious mix-ups and dating experiences, illuminating how their shared love for music intertwined with their romantic ties. Through candid discussions of their life together, career achievements, and shared memories, you'll glimpse how their love transcends the chaos of the entertainment industry, strengthening through trials and tribulations, and provides a refreshing blend of humor, love, and realism.  Also, we talk about Cat's experience with the "Dear Juliet" club in Verona, Italy, and Victorian-era practices like pinning bay leaves to your pillow to attract love. An interesting backstory of Necco candy hearts, and the probably best forgotten tradition of "Vinegar Valentines" are also discussed. We hope you enjoy this sweet and fun episode!

Who would have thought that the hardest button to button was that of candy all along. This week we're trying the infamous yet iconic candy buttons. We'll get into their very old history and get to the bottom of if they live up to their reputation. Grab a pad of them and eat along with us!

Yobo, Daniel, Matt, and Mike talk about the reunion of Cameron Mitchell and Leo Fong! It's a Camvember miracle, right? right?!  Featuring Cameron drooling over a teppanyaki, extended talk about Necco wafers, and Daniel's new rap persona.  

Necco wafers. Book Club. Whacked by a whale. McFlurry spoon. Quit smoking on Monday. City of College Station update. Retirees don't want to move to Florida. New resort in Vegas.

Carolina. Windshield wipers. Back in 2018. Transformer. Fall is coming. Google maps. Should Halloween always be on a Saturday? Worst Halloween candy. Necco wafers. Book Club. Whacked by a whale. McFlurry spoon. Quit smoking on Monday.

Holmberg's Morning Sickness - Brady Report - Thursday October 26, 2023 Learn more about your ad choices. Visit megaphone.fm/adchoices

Holmberg's Morning Sickness - Brady Report - Thursday October 26, 2023 Learn more about your ad choices. Visit megaphone.fm/adchoices

Savanna from Necco Foster Care is on the show this morning! Necco is holding an open house on Monday, October 2nd, from 6:00 PM to 8:00 PM. Join them for food & raffle prizes! They're located at 178 Private Dr. #19423, South Point, Ohio. You can call them at : (740) 263-2626 or visit their website at : www.necco.org.

Do you ever feel like the world revolves around you? Well, it certainly did for Robert Todd Lincoln AKA The Angel of Death. Come learn of the macabre curse that was responsible (possibly) for the deaths of no fewer than three American presidents! And a Beatle even! Other discussion topics may include: - A celebration of musical legends, like Drew Lachey and Rhea Perlman - Presidential assassinations and other forms of light porch vandalism - Three words: Gangster Rain Man - Do short people *actually* age? Or is it all a hoax? - Tales of the finger pickin', the oyster lickin', and the curse stricken --- Send in a voice message: https://podcasters.spotify.com/pod/show/goingterribly/message

Frizz and Bob join forces with Lord Bael to dig into the depths of the heavy metal with Black Sabbath's monumental album, Paranoid, and share a hefty splash of Wilderness Trail Rye. Join us as we chat about Ozzy's lack of self awareness, the secret behind how Sabbath changed the way we heard rock music, Geezer Butler's encounter with the devil, Good n' Plenty and Necco wafers, and all things bad times. Cheers!

The Jackson City Library is on the show with us to talk all things going on in the library! The library has many events going on this summer so make sure to watch this morning and see what's happening at the library! Did you know there are over 16,000 children in the Ohio foster care system that need a safe, stable and loving foster family? Even if its short or long term. Later in the show were going to be talking about how to how to become a Foster Parent!

Necco, aka the New England Confectionery Company, was the oldest candy company in the United States at the time of its closure in 2018. Based here in Revere, Massachusetts, the company played a historic role in the world of American candy. Necco manufactured national favorites like Clark Bars, Candy Buttons, Sky Bars and Sweethearts. But their bestseller was without a doubt the Necco wafers, dating back to 1847. Interestingly, Necco marketed its wafers in a number of ways. Darlene Lacey, an author and curator of the Candy Wrapper Museum, told Under the Radar that the company wasn't really sure how to position the candy. "In the early times, they focused on them being the perfect treat for hostesses at afternoon teas. They had them described as a 'fairy feast' in a garden of delights. Very delicate, very romantic," she described. "... And then as time went on, they started to skew them a little bit more towards kids, and then later into the nostalgia market." The company was sold a handful of years ago to the Ohio-based Spangler Candy Company. But how did this shift impact the candy manufacturing world? Under the Radar talked with Lacey about everything from favorite sweet treats to the future of the candy production industry.

Mike Armstrong and Brendan Hayes give an update to the Taylor Swift index. Ford is planning to cut thousands of jobs in Europe as it prepares to be more heavily invested in EV production in the US. Crypto investors brace themselves for regulatory crackdowns. Necco may have gone under, but their sweetheart candies will last forever. Laid off tech workers are seeking leverage on their way out. Corey Adams, Regional President at Robert Half, discusses the current state of the Boston labor market.

Love is in the air so let us whisper sweet reviews in your ears. This week we're reviewing the iconic and divisive Sweethearts in time for Valentine's Day. Grab a box and eat along with us!

It is November the 15th, welcome to a brand new Waking Up with Nate & Smitty on National Clean Out Your Refrigerator Day. We have a wonderful show in store for you today. We have horoscopes, Top 20 US States with the most Veterans, and Nate is going to eat Neccos & Candy Corn .-----------------------------------------------------------------------------WATCH MORE AND SUBSCRIBE: ►►https://www.youtube.com/channel/UCl1os4MvHVCVgUc3AosFSNw#TalkingStuff #TalkingStuffPodcast #WakeUp-----------------------------------------------------------------------------CONNECT WITH US!Email: talkingstuffpodcast@gmail.comVoicemail/ text: 850-307-5221Follow us on Twitter at: https://twitter.com/podcast_stuffFollow us on Instagram at: https://www.instagram.com/talkingstuffpodcastnetwork/-----------------------------------------------------------------------------SPONSOR: ►► Make amazing coffee at home with Magia Coffee. Shop their delicious coffee and have it shipped right to your door. Go to https://www.magiacoffee.com/ and use the Discount code “WAKEUP” to save 10% on your purchase.Magia Coffee is veteran owned and shipped from South Carolina

Hey folks! Welcome back to the best couch guided safari this side of the states. We hope you enjoying listening and learn a little something too. This week, we discuss the annual anguish of unwanted candy, and what to do about Joshua's new visitor. Thanks to our amazing sponsors this week, Bush's Baked Beans and Jon Finch. As always please say hey @Nicol_park_podcast or Nicolparktours@gmail.com. And tell someone about the show! 

Our pal Blasted Bill returns to the Flopcast for some Halloween talk! Bill shares his memories of Halloweens past as well as the 8,000 Halloween events he has planned for this year. (That certainly beats our big Halloween plan to do nothing...) Including: Superman, Ghostbuster, and red crayon costumes; hay rides vs. straw rides; trick-or-treating aboard the beer tractor; a defense of Necco wafers; scary cousins in the cemetery; Hocus Pocus drinking games; building your own coffin; freaking out your Uber driver; butter beer vs. Zima; Scooby Doo-costumed bar crawls; a peanut butter pumpkin possum; and lots more seasonal silliness. Plus: Matt concludes his Boo Berry review, Bill is on TikTok, Kevin is on The Batcave Podcast (talking Electra Woman and Dyna Girl) and Gleaming the Tube (talking The Commitments), and Kornflake might be a Yip Yip. Blasted Bill on TikTok! Our latest Electra Woman review on The Batcave Podcast! Reviewing The Commitments on Gleaming the Tube! And our regular links... The Flopcast website! The ESO Network! The Flopcast on Facebook! The Flopcast on Instagram! The Flopcast on Twitter! Please rate and review The Flopcast on Apple Podcasts! Email: info@flopcast.net Our music is by The Sponge Awareness Foundation! This week's promo: Thunder Talk!

Snacks in this episode: - Necco wafers - Charms hard candy - Canel's gum 

Nevertheless Josiah would not turn his face from him, but disguised himself, that he might fight with him, and hearkened not unto the words of Necho from the mouth of God, and came to fight in the valley of Megiddo.

This week on Under the Radar: New England Confectionery Company, or Necco, was the oldest continuously running candy company in the country up until its closure in 2018. The company, which was based in Revere, Massachusetts, produced Clark Bars, Mary Janes, Candy Buttons, Sky Bars, Squirrel Nut Zippers, Sweethearts, and — most notably — Necco Wafers. The New England Confectionery Company shaped the candy industry in our region and beyond, and its closure shocked sweettooths across the country. But the historic Necco candies are living on, produced by the Ohio-based Spangler Candy Company. We're talking all things candy, confections and the future of our region's sweets industry. GUEST: Darlene Lacey, an author and curator of The Candy Wrapper Museum. Her most recent books are “Necco: An Epic Candy Tale” and “Necco: The Archive Collection.”

It's the lost Spring Sessions as we relocated to the new Bean Bag Studios 3.0. We've got a roll of Necco wafers and some airplane editions of Who Sucks More? amount other things as we roll on a soft launch for the upcoming Grand Opening.

For Mother's Day, we have a special bonus! Megan's mother Karen stops by to talk about mothers and daughters in the movies!  We start with our snack review. Necco wafers were one of Karen's favorites... and something Megan avoided. Then, we revisit the original 1970s version starring Jodie Foster and Barbara Harris and talk about the gender roles and generational differences in the movie. Then, we look at the early 2000s remake starring Lindsay Lohan and Jamie Lee Curtis. Which did we like best? Listen to find out! Visit our blog to watch along with us at www.stopruiningmychildhood.com

Our guest from Episode #067, Parag Shah, foresaw the death of penmanship - something he happily announced at age 8. That didn't save him from having to write a page of QBasic code each day before he could go out to play! Topics discussed include how serious you get about studying when you are paying your own tuition, decoupling storage and compute, and handling turnover at the top.   https://learn.dvorak.nl/ https://www.umass.edu/living/residence/northeast https://en.wikipedia.org/wiki/Necco https://www.forcepoint.com/cyber-edu/shadow-it

For decades, Necco was the pride of New England candy-making. The iconic company, based in Revere, has been closed for a few years now, but there are still plenty of stories to be told. Darlene Lacey, an author and “candy historian” from Los Angeles, California, has been exploring the extensive history of the candy – and the people – behind the New England Confectionary Company. She's releasing a new book about it, “Necco: An Epic Candy Tale”, and she joins Nichole to talk about her research. The weather's getting warmer, and the sun's going down later, which means it's time for us to spend more time outside. That also means it's time for mosquitoes to start showing up – along with the West Nile Virus and Eastern Equine Encephalitis! Dr. Catherine Brown, State Epidemiologist at the Massachusetts Department of Public Health, has all you need to know about the viruses, what the state is doing to try and protect the public, and how you can protect yourself from those pesky mosquitoes.

Stacy shares a ridiculous story about a random dog named Joe and two of her cats, Percy and Finn that exemplifies the ridiculousness of her life. She and her guest, Emily McPhetridge talk about motherhood and how to navigate it when nature versus nurture are at war. Stacy also feels SUPER old mentioning references from NECCO wafers to Cheers that Emily doesn't get at all!

Hop on the eclair canoe and take a terrible trip on the corn syrup seas! And make sure to take your insulin shot while you're at it because this is a much crueler Candyland than you're used to. Plus: Ian tries to steer Travis away from his crippling sugar addiction, Travis attempts to dive nose first into a pile of pixie stix, and Adron continues to be the Necco-white backbone of the show.

If you believe people deserve to know the expectations for their performance, this is the podcast for you! Beau Necco, CEO of Necco Foster Care and Rob Goodwin, Necco's Chief People Officer join me to in this first of three podcasts on setting expectations with our people and how they use this process to help their managers "grow people". Of all of my clients, Necco has put the most work into making this discipline a true competitive advantage. You'll enjoy learning about the journey they have been on and the things they have learned.

Ed is a leading global expert in professional management, sales strategy, and performance management. He is a former principal consultant for the Table Group, a Patrick Lencioni Company, and operates The Eppley Group. He has worked with executive teams at multinational companies across the U.S., Europe, China, Japan, and Australia. His clients include a “Who's Who” of business category leaders such as BMW, DSW, Sara Lee, Bloomberg, Battelle, Goodyear Tire and Rubber Company, Speedway, Steamboat Ski & Resort Company, Value City Furniture, PSA Airlines, Emerson Electric, NECCO, Safelite Auto Glass, and others. A life-long entrepreneur, Ed started an advertising agency and a manufacturer's rep firm selling to the industrial and construction markets before creating Tyson Eppley Management, ProspeX, and The Eppley Group. If you want to benefit more from Ed's wisdom, clarity and straight talking professional management advice you can get his book, “Let's Be Clear” from Amazon and you can listen to his podcast, The Ed Eppley Experience wherever you listen to your podcasts.  This is the 50th episode of CAREER-VIEW MIRROR and I wanted to celebrate this milestone by introducing you to a guest who is very special to me and who has had a significant impact on my own development, career and life journey. I first met Ed in 2006 in South Africa when he was facilitating an international leadership development programme that I was attending as part of my integration into my new region at BMW. Ever since meeting him he has been challenging me in his inimitable way to become the best version of myself. For that I am hugely grateful. It is an honour, a privilege and a huge pleasure to be able to introduce Ed to you in this way and to invite him to share his inspiring story. As always, I look forward to hearing what resonates with you.  You can contact Ed via LinkedIn or via email: ed@theeppleygroup.com Why not follow us on Instagram @careerviewmirror where you can see a directory of all our episodes and comment on those you have enjoyed. To help you navigate the content we've separated it into chapters which work on Apple Podcasts and certain other streaming platforms. This episode of Career-view Mirror is brought to you by Aquilae.  Aquilae is a boutique consultancy in the auto finance and mobility industry. We offer our Expertise as a Service to help you design and deliver projects that develop your business and the people within it. Contact cvm@aquilae.co.uk if you'd like to know more. If you enjoyed this podcast please take a moment to leave a review on Apple Podcasts. Your feedback helps us grow. For details of our forthcoming guests follow us on Instagram @careerviewmirror Email: cvm@aquilae.co.uk Twitter: @andyfollows Episode recorded on 17 January 2022 

This month are hearts are all a-flutter, and it's not just because of our love of crappy NECCO wafers. We're seeing stars about our February topics! We'll be joined by Dr. Patrick McGreevy to discuss the origins and utility of the “Essential for Learning” curriculum followed by a review on the literature regarding teaching abduction prevention skills to children. As a special surprise, we've also got our 2021 talk from the Thompson Center for Autism Conference on maintaining a work-life balance. And, for our Patreon supporters, the latest in our Book Club series where we'll be analyzing “Look Me in the Eye: My Life with Asperger's” by John Elder Robison. Now check the candy heart in your podcast player: It says, “Cool Cat”. That's you! Articles for February 2022 Essential for Living w/ Dr. Patrick McGreevy McGreevy, P., Fry, T., & Cornwall, C. (2012, 2014). Essential for living. Orlando, FL: Patrick McGreevy, PhD, P.A. and Associates. McGreevy, P. & Fry, T. (n.d.). A journey to life skills. Essential for Living. https://essentialforliving.com/efl/ Armstrong, H., Denne, L.D., & Bailey, T. (2021). The role of key skills as a risk marker for the development of challenging behaviour in children and young people who have an intellectual disability. International Journal of Positive Behavioural Support, 11, 3-14.   Abduction Prevention Gunby, K.V., Carr, J.E., & LeBlanc, L.A. (2010). Teaching abduction-prevention skills to children with autism. Journal of Applied Behavior Analysis, 43, 107-112. doi: 10.1901/jaba.2010.43-107 Miltenberger, R.G., Fogel, V.A., Beck, K.V., Koehler, S., Shayne, R., Noah, J., McFee, K., Perdomo, A., Chan, P., Simmons, D., & Godish, D. (2013). Efficacy of the Stranger Safety abduction-prevention program and parent conducted in situ training. Journal of Applied Behavior Analysis, 46, 817-820. doi: 10.1002/jaba.80 Berube, T., MacDonald, J., & Parry-Cruwys, D. (2021). Teaching abduction prevention skills to children using a one-on-one training setting. Behavioral Interventions, 36, 550-560. doi: 10.1002/bin.1806 Ledbetter-Cho, K., Lang, R., Lee, A., Murphy, C., Davenport, K., Kirkpatrick, M., Schollian, M., Moore, M., Billingsley, G., & O'Reilly, M. (2021). Teaching children with autism abduction-prevention skills may result in overgeneralization of the target response. Behavior Modification, 45, 438-461. doi: 10.1177/0145445519865165   Bonus: “Work Life Balance as a BCBA: Is it Even Possible”   Winter 2022 Book Club Robison, J.E. (2007). Look me in the eye: My life with Asperger's. Crown Publishers.

In this episode, Linden and Layton talk about one of the first candy brands, NECCO. Dig in with them as they discuss this New England original. If you have a topic suggestion or want to get a hold of us, here are a few ways | email: hardcrack@lindenaho.com | Instagram: https://www.instagram.com/hardcrackpodcast | Linden's Twitter: https://twitter.com/lindenaho | Layton's Twitter: https://twitter.com/laytonaho This episode was delayed due to technical difficulties. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/hard-crack/message Support this podcast: https://anchor.fm/hard-crack/support

Unfortunately, we lost a recording and have to push the release of the Necco episode. Thanks for the support and understanding --- Send in a voice message: https://anchor.fm/hard-crack/message Support this podcast: https://anchor.fm/hard-crack/support

Travel Gluten Free Podcast Episode 157 Rerun Gluten Free Halloween Candy   Listen in to this rerun of Gluten Free Halloween Candy and find out why brands you can normally trust have a different manufacturing process during the holidays. We know what happens when new food prep is involved - the addition of the potential for cross-contamination. Know which brands are safe to eat during the upcoming Halloween Holidays and which candy you want to stay away from if you're gluten-free.   The Guide to Traveling Gluten Free Are you anxious about traveling with Celiacs Disease? Does the thought of getting sick on vacation worry you to no end? Unsure of what travel options are safe and how to choose a safe restaurant away from home for you and your children? The Guide to Traveling Gluten Free will walk you through the process of planning and enjoying your next gluten-free travel adventure! Take the guesswork out of how to travel. Learn how to take a trip safely, what questions to ask when you are at a restaurant and which online tools and apps to utilize to find safe, dedicated gluten-free restaurants and food options. Find out what stores to shop at to purchase gluten-free food, determine if a restaurant is gluten-free or celiac friendly, and when you should walk out of a restaurant.  Links and Resources Mentioned   Contact Information Just Born | 888-645-3453 Necco | 781-485-4800 Hershey's | 800-468-1714 Mars Chocolate | 800-627-7852 Nestle USA | 800-225-2270 Tootsie Roll Industries | 773-838-3400 Wrigley | (800) 974-4539 Ferrero (Tic Tac) | 732-764-9300   Happy 30th Birthday to Our Sponsor Kinnikinnick!   Kinnikinnick is celebrating its 30th birthday and is offering Travel Gluten Free listeners a 10% discount when you use the code TravelGlutenFree at checkout! Order $55 or more and receive your discount when you checkout in your cart! Then, fill your cart with one of Kinnikinnick's new goodies, such as their chocolate chip cookies, their soft and fluffy hot dog buns, and their flatbread crusts.    Journey with Travel Gluten Free Get the BEST all-natural gluten-free travel cosmetics at Lemongrass Spa!  Find cool gluten-free swag at my gluten-free swag shop The Guide to Traveling Gluten Free will walk you through planning and enjoying your next gluten-free travel adventure!   Follow Travel Gluten Free on Social Media  Twitter, Facebook, Youtube, Pinterest, Instagram   *Spread the love of Travel Gluten Free podcast and share this episode with a friend*

Harry's guest this week is Jeff Elton, CEO of a Boston-based startup called Concert AI that's working to bring more "real-world data" and "real-world evidence" into the process of drug development. What's real-world data? It's everything about patients' health that's not included in the narrow outcomes measured by randomized, controlled clinical trials. By collecting, organizing, and analyzing it, Elton argues, pharmaceutical makers can it design better clinical trials, get drugs approved faster, and—after approval—learn who's really benefiting from a new medicine, and how. Concert AI, which has offices in Boston, Philadelphia, Memphis, New York, and Bangalore, specializes in providing “research-grade real-world data” and AI-based analytical services to companies developing cancer drugs. Before joining Concert AI, Elton was managing director of strategy and global lead of predictive health intelligence at Accenture, and before that he was a senior vice president of strategy and global chief operating officer at the Novartis Institutes of BioMedical Research. He's the co-author with Anne O'Riordan of a 2016 book from Wiley called Healthcare Disrupted: Next Generation Business Models and Strategies.Please rate and review MoneyBall Medicine on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:• Launch the “Podcasts” app on your device. If you can't find this app, swipe all the way to the left on your home screen until you're on the Search page. Tap the search field at the top and type in “Podcasts.” Apple's Podcasts app should show up in the search results.• Tap the Podcasts app icon, and after it opens, tap the Search field at the top, or the little magnifying glass icon in the lower right corner.• Type MoneyBall Medicine into the search field and press the Search button.• In the search results, click on the MoneyBall Medicine logo.• On the next page, scroll down until you see the Ratings & Reviews section. Below that, you'll see five purple stars.• Tap the stars to rate the show.• Scroll down a little farther. You'll see a purple link saying “Write a Review.”• On the next screen, you'll see the stars again. You can tap them to leave a rating if you haven't already.• In the Title field, type a summary for your review.• In the Review field, type your review.• When you're finished, click Send.• That's it, you're done. Thanks!Full TranscriptHarry Glorikian: I'm Harry Glorikian, and this is MoneyBall Medicine, the interview podcast where we meet researchers, entrepreneurs, and physicians who are using the power of data to improve patient health and make healthcare delivery more efficient. You can think of each episode as a new chapter in the never-ending audio version of my 2017 book, “MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market.” If you like the show, please do us a favor and leave a rating and review at Apple Podcasts.Harry Glorikian: In the world of drug development, there's a tendency to think that the only data that matter are the data that get collected from patients during randomized controlled clinical trials. That's the type of study that drug companies use as the gold standard to test the safety and effectiveness of new drugs and that the FDA uses to make drug approval decisions. But it's just not true. Way before clinical trials begin, there's a ton of genomic or proteomic or chemical data that can go into identifying new drug candidates, as we've learned from many of our previous guests on the show. And today my old friend Jeff Elton is here to tell us about another important kind of data that get collected before, during, and even after clinical trials that can have a huge impact on how drugs are used.It's called real-world data, and it basically means everything about a patient's health that isn't included in the narrow parameters and outcomes measured by clinical trials.Jeff is the CEO of a startup here in Boston called Concert AI that specializes in organizing and analyzing this real-world data. And his argument is that when you pay attention to real-world data, it can help you to design better clinical studies. It can help support the core clinical data that drug companies submit to the FDA when they're applying for approval. And after approval, it can help show who's really benefiting from a new medicine, and how. Jeff has been thinking about the importance of real-world data for a long time, at least since 2016, when he leading predictive health intelligence at Accenture and he published a book called Healthcare Disrupted. The book argued that real-world data from wearable devices, the Internet of Things, electronic medical record systems, and other sources could be combined with advanced analytics to change how and where healthcare is delivered. In our interview, I asked Jeff to explain how Concert AI is helping patients and how the predictions he made in the book are playing out today.Harry Glorikian: Hey, Jeff, welcome to the show. Jeff Elton: Thank you Harry. Pleasure to be here. Harry Glorikian: Yeah, it's been a long time since we've actually seen each other. I mean I feel like it was just yesterday. We were you know, interacting. Arshad was there and we were talking about all sorts of stuff. It's actually been quite a few years and, and, and you have now transitioned to a few different places and, and right now you're running something called Concert AI. And so, I mean, let's just start with what is Concert AI, for everybody who's listening. Jeff Elton: Yeah. So Concert AI is a real-world evidence company. We'll spend a little bit of time breaking that down. We are very focused on oncology, hematology, urological cancers. So we kind of tend to stay very much in that space.And within the real-world evidence area, we really focus on bringing together high credibility research grade data. This usually means clinical data. Genomic data can include medical images combined with technologies that aid gaining insights out of those particular data and that kind of align with our own various use cases.A use case could be designing a clinical study, it could be supporting a regulatory submission. It could be gaining insight, post-approval, about who's benefiting, who's not benefiting. And you know, our whole mission in life is accelerating needed new medicines and actually improving the effectiveness of current medicines out there.Harry Glorikian: So who's like, I don't know, the user, the beneficiary, in a sense, of this.Jeff Elton: So, you know, we like to think we have a very heavily clinical workforce. You know, we always put the patient first. So I'm actually gonna say that a lot of the reason why we're doing things is that we have the benefit to be stewards, combined with provider entities, of focusing on questions that matter for patient outcomes.So the first beneficiary is patients. I think the second beneficiary are biomedical innovators. We're trying to kind of support those innovations. We're trying to understand how to go into the clinic. We're trying to understand how to design those clinical trials to have them be more effective. We're trying to understand how to show that relative to the current standard of care, they offer a range of incremental therapeutic benefit. A lot of medicines become improved once they're actually already approved. And so we actually spend time doing a lot of post-approval research that actually begins to improve the outcomes by beginning to kind of refine the treatment approaches.And then the clinical communities we work very closely [with]. We're a very close working partner with American Society of Clinical Oncology and their canceling program. We're in a 10-year relationship with them that allows us to do work in truly high need areas. We did a COVID-19 registry jointly with ASCO that worked off of some of the data we brought together because it you know, COVID-19 uniquely hit cancer and particularly hematological malignancy patients.We do work with them in health disparities, making sure that racial, ethnic, and economic groups can be the beneficiaries of new medicines and are appropriately part of doing clinical trials, clinical studies. And then we work directly with provider communities who oftentimes are seeing the value of the work we're doing and making sure that for research purposes, we have appropriate access to data, information to conduct that research.Harry Glorikian: Yeah. I want to get into, you know, I think we're going to, I'm going to hit on some of that later, but I just want to make sure everybody's sort of on a level playing field with some of these wonky terms we use. How do you define real-world data and real-world evidence. I mean, I know what the FDA defines it as. I'm just curious. Jeff Elton: Yeah. So yeah. And FDA does have some, they have some publications really there that came out at the end of 2018 that actually began to lay out a framework around that, which I would encourage folks to reference. It's actually a very well-written document.So real-world data is sort of what it sounds like. It's the data. Right. And You know, if you were a clinician, if you were sitting in a clinical care environment, you probably wouldn't be using the word real-world data because those are the data generated through your treatment of the patient. So clinicians sometimes actually kind of pause for a moment to say, what's real-world? It's the things I'm doing. And in fact, you know, real-world data would be structured data in a structured field. It's a lab value that may have come in from the laboratory information system or a drop down menu. Did they smoke or not? Which can be a fixed field in an EMR. All the way over to physician notes, to appended molecular diagnostic reports, to imaging interpretation reports.So all those are forms of data. Now, evidence is a little bit about also what it would sound like. Data are not evidence. You have to actually, and in fact, to generate evidence, I want to have to trust the data. I have to believe those data are an accurate reflection of the source systems they came from. I have to believe they're representative or appropriate for the question that I'm actually trying to address. And then I have to make sure that the methodologies I'm using to analyze something, either comparing the effectiveness of two drugs relative to each other, actually then when I look at that analysis, I'm willing to either make a regulatory decision or a guideline modification.And the intent of evidence is either to support a regulatory decision or something that can inform practice of medicine or nature of treatment. So there's a bar, right, that one has to achieve to actually become evidence. But I think evidence is the right goal by what we're trying to do.Harry Glorikian: So you know, in the past, I mean, because I've, worked with companies like Evidation Health and so forth right there, some of this data was in paper form, right. Not in electronic form. So, what holes in the current system of, say, drug development would better real-world data or real world evidence help fill or, or drive forward.Jeff Elton: Yeah, that's a super good question. And, you know, Harry, you were kind of going back to your, I mean, you were one of the primary, leading individuals around that when the days of personalized and individualized and precision medicine, and even some of molecular medicine kind of came around. In fact, that's probably where you are my first point of interaction.And I come back to that concept because when you, when you're looking at data—and again, not all data are kind of created equal here—when I think about setting up and designing a clinical study, so now I'm with an experimental therapeutic or I'm thinking about moving it in. If it worked in one solid tumor and I suspect that same molecular pathway or kind of disease mechanism may be at work in another one. And so I want to kind of think about doing a pan tumor strategy or something of that nature. When I actually, when I, if I can bring together molecular diagnostic information, aspects of the individual patients, but do it at scale and understand the homogeneity, the heterogeneity and the different characteristics in there, I can design my trials differently and I can make my trials more precise. And the more precise the trials are, the higher the likelihood that I'm going to get meaningful outcomes. The outcomes here that are meaningful is what actually helps medicines progress. It's actually getting those questions to be as narrow and as precise and as declarative in their outcomes as possible.And so a lot of these data can actually be used to help guide that study design. Now, if I also have very rare cancers or very rare diseases—so this would apply even outside of oncology, although most of our work is oncology related—even if I'm outside of that, if I'm in very rare, oftentimes finding, you know, putting a patient on a  standard of care therapy as a control oftentimes may not be in the patient's best interests. And so this notion of either a single arm or having an external control or having a real-world evidence support package, as part of that, may be part of what can occur between the sponsor and actually the FDA, et cetera, for kind of moving that through.But, you know, this has to be done individually around the individual program and the program and the characteristics have to kind of merit that, but these are big deals. So we feel that these are forms of data that can complement what would have been traditional legacy approaches to give more confidence in the decisions being made in the evaluation, the ones actually coming, too.Harry Glorikian: Yeah, I can hardly wait. I mean, maybe it's a dream, but I can hardly wait until we get rid of first-line and second-line and we just say, okay, look, here's a battery of assays or whatever. This is what you should be taking. No more first line or second line. I mean, these are sort of in my mind, I mean, almost arcane concepts from, because we didn't have the tools in the past and now we're starting to move in that direction.Jeff Elton: Yeah. So, Harry, just to, maybe to build on that a little bit. So if you look at some of our publications and things that we presented at this last ASCO, there's work one can do when you look at different features of patient response, et cetera. We're a company, but we also have a very strong data science backbone to what we do. And AI and ML applications. There are features that sometimes you can predict metastatic status. You can predict rate of response. You can predict progression. Now the very fact that I can make that statement kind of indicates that as you started thinking about the paradigm in the future, particularly when I start doing it liquid tumor, biopsies and surveillance mechanisms where I can see response much more rapidly in less invasive ways, you are going to start even over the course of this next five years, I think some of these will start to start influencing practice patterns in some very positive ways for patients, Harry.Harry Glorikian: From your lips to his or her ears. It needs to move faster. But, but it's interesting, right? I feel like you've been on this path for quite some time, like, I want to say since you're at least since your book in 2016, if not before. Jeff Elton: Yeah. So, you know yeah, you and I, in fact, you and I interacted first, I think we were kind of in the hallways, first interaction of what had been the Necco candy factory on Massachusetts Avenue in the Novartis building, where I was working in the Novartis Institute for Biomedical Research at the time.And Even prior to that, I think I did my first work back in the days of Millennium Pharmaceutical when it was still a standalone company, doing work in precision medicine and personalized medicine all the way through. And obviously Novartis's strategy was looking at pathway biology and actually using that as the basis of actually understanding where in a pathway system one could actually target and actually understanding that it is a system, it's got redundancy both in a bad, in a positive way. How do we use it to progress new medicines? So there's been an aspect of this that's always been kind of a little bit hard. I think I kind of made a decision to kind of pivot much more to a large scale data-centric, insight-technology-centric approach, and actually at scale, bring some of that back to the biomedical innovators. But yeah, it's been a progression over time and some of this it's a field that I feel, you know, strong passion around and will stay committed to for the duration of whatever my professional career looks like.Harry Glorikian: So can you give us maybe an example? I mean, I know some of it may be confidential. How does the data that you're providing, say, improve maybe drug safety or effectiveness? Jeff Elton: So you know, we're doing a project right now that that's safety related and I'll kind of try to keep it such that it I'm not betraying anybody's confidence. Eventually this will be in a publication, but it's not at the point yet. We're looking at a subpopulation that had severe adverse events, cardiac adverse events in the population. And originally the hypothesis was, it was a relatively homogeneous group. And we brought together some of our deepest clinical data, which means we have many different features of intermediate measures of disease, recurrence, progression, response, adverse events, severe adverse events. And we also brought some of our data science and AI solutions to it. And one of the major insights that came out of that is actually it wasn't a single homogeneous group. One group was characterized by having a series of co-morbidities that then linked to this significant adverse event and the other were purely immunological based.And so therefore actually in both cases, they're screenable, they're predictable. They're surveillable. And monitorable. And so therefore, but the actions would be very different if you didn't know what the two groups are. So in this particular case, we could discriminate that now. Well, we'll take that into more classical biostatistical analysis and do some confirmatory work on that, but that has significant implications on how you're going to kind of screen a patient survey of patients, look for whether or not they exhibit that area, and how you would kind of handle it, manage that. That would improve the outcome significantly of that subpopulation.So that's one example. In other areas, some of our data was actually being used as part of a regulatory submission. It was a very, very rare population in lung cancer. And it was unclear exactly how nonresponsive they were to the full range of current standard of care. And we were actually illustrating that there was almost a complete non-response to all current medicines that were actually used against this particular molecular target because of a sub mutation. And that actually was part of the regulatory submission. And that program both actually got breakthrough designation status, and that actually supported that and actually got an approval ahead of the PDUFA date. So when you start pulling some of these pieces together, they work to again, provide more confidence and interpretation and more confidence in decision-making. And in this particular case, certainly accelerated medicines being available to patients. Harry Glorikian: Oh yeah. Yeah. Drive value for patients and drive value for the people that are using the, the capability to get the product through. So, you know, we're talking about data, data, data. At some point, you've got to turn this into a product or a service of some sort or, or some, or maybe a SaaS as, as, as you guys might look at it, but you've got something called, you know, Eureka Health, right, in your product lineup. Can you give us an idea of what that is? I think it's a cloud-based SaaS product. You call it research-ready real-world data. So I'm just curious how that works. Jeff Elton: Yeah. So we do think.. So if you think about what we're trying to do, we're trying to allow a level of scale and a level of precision and depth on demand in the hands of individual researchers, from translational scientists, folks in clinical development, post-approval medical value and access. Kind of in that domain. And so each of those have different use cases. Each of those have different kind of demands that they'll place on data and technology for kind of doing that.We're trying to move away from the world of bespokeness, because by nature of bespokeness, the question has its own orientation. The data is just unique to the question and that utility later is very low and, you know, in a way, what we'd rather do, what have we learned about what actually kind of create utility out of data, and let's make sure that we're covering the use cases of interest, but let's do it at very large scale. And that scale itself and the data we even represent at that very large scale is in itself representative and actually has significance whether it's on a prevalence basis of sub cohorts of disease or not. Now, the reason why I'm spending so much time developing that is when you put that in the hands of the right people, you're avoiding bias, but you're also giving utility at the same time and so you're actually improving their ability to conduct rapid question interrogation, but also structure really good research questions and have the discipline if I have a good research methods right around that. So we do structure those as products.And so, so actually one of the things we think of is, the work that we do in non-small cell lung cancer is an extremely large data set. It also has high depth on the molecular basis of non-small cell lung cancer. And it's created in a way that actually allows you to make those questions from translational through post-approval medical and doing that.Eureka is the technical environment. It is a cloud environment we are working in, and it actually allows you to do on-the-fly actually insights. So, outcome curves, which are called Kaplan-Meier and a few other measures. I can compare groups. I can compare cohorts. I can ask questions. It's actually exceptionally fast.And so this ability to navigate through a series of questions, its ability to make comparisons of alternative groups of patients on different classes of questions and finally get down to the patient cohort of interest that you may want to move into in the next phase, your research is done a lot faster. Now we took that, and now we're integrating more AI and ML into that. So we now have created probably what's one of the leading solutions for doing clinical study design. So we can optimize different features of that study design. We can actually release lab values. We can change parameters. There's a level of kind of fitness, ECOG scoring. We can actually modify that and show what the changes would be in the addressable patient population, and actually optimize that study design all the way down to the base activity level. And we're basically creating a digital object that's rooted on huge amounts of data. Underneath the 4.5 million records runs inside that particular area.There is no other solution in oncology, hematology that gets anywhere to that depth of information that can reflect, with different optimization, to the endpoint and even reflect statistical power. Now we're integrating in work around health disparities. How do you assure that if it's a disease like multiple myeloma, which may disproportionately affect black Americans, that I'm actually getting adequate representation of the groups that in fact, actually may be afflicted by the disease and actually assure the design of the study itself assures their representativeness actually in that work?Harry Glorikian: This dataset, what are some of the features of it? What is it? What sort of information does it have in it that you would be pulling from? Because my brain is like going on all sorts of levels that you would pull from, and some of it is incredibly messy.Jeff Elton: Yeah. So you are absolutely right. And so there have been expressions in the field of people who do work in real-world data that the real world's messy you know, fields may be empty. Do you know, as an empty field, because nothing got put there where's the empty field, because in that electronic medical record environment empty means it was not true of the state of the patient. That may sound like a nuanced thing, but sometimes empty actually is a value and sometimes empty is empty. And so you start getting into some things like that, which you start thinking about, like, those are pretty nuanced questions, but they all have to do with, if you don't know which it is, you don't know how to treat and move the data through.So back to your question here a little bit. What we actually, the sources of where we bring data from are portions of a clinical record. So, you know, we work under businesses, the work we do is either research- or quality-of-care-focused. And so, you know, we work actually, whether it's with the American Society of Clinical Oncology and et cetera, appropriately under all HIPAA guidelines and rules for how you interact with data around doing that. So I'll put that as a caveat because methods and how you do that security and everything else is super, super important. We have a clinical workforce. These are all credentialed people. Most of them have active clinical credentials. Most of them were in the clinic 10 to 15 years and even still interact on it. So a lot of my people feel they're still in clinical care. It's just happens to be a digital representation pf the individuals that are in there. And we're seeing, whether it's features of notes, depth of the molecular diagnostic information, radiologically acquired images that may show how the tumor progressed, regressed, et cetera, that's in there, any other, the medications, prior treatment history, comorbidities that may confound, actually, response. So all those different features are brought together, but if you don't bring it together consistently, we have tens of thousands of lines of business rules, concepts, and models that we try to publish around about how you bring a concept forward.So if you want to bring a concept forward, want to do it consistently, we come out of 10 different electronic medical record environments, and we're, we're actually interacting with the work of 1,100 medical oncologists and hematologists, et cetera. You have a lot of heterogeneity. Handle that heterogeneity with a clinical informatics team into a set of rules as it's coming forward so that everything comes to the point that you can have confidence in that, you know, in that particular analysis and that presentation.So there's something called abstraction, which is a term applied to unstructured data—and unstructured just means a machine can't read it on the fly. And so we're actually interacting with that, which could have a PDF document or something else. And from that, we use the business rules to then develop something that now is machine-readable, but actually has a definition behind it that one can trust, that one can, that kind of comes from some published basis about why did you create that variable? So I could measure outcomes of interest progression-free survival, adverse events, severe, whatever the feature of interests can. Help me answer the question we try to kind of bring through. So we're usually creating about 120 unique variables that never would have been  machine-readable, in addition to the hundred, that probably were machine-readable when we bring that together. Harry Glorikian: So you're using a rule-based AI system, maybe not just a straight natural language processing system, to parse the words.Jeff Elton: Yeah. So natural language processing gets a little tricky. We do. We have, actually, excellent natural language processing. We'll sometimes use that for pre-processing, but you have to be careful with natural language processing. If it has context sensitivity, and if you're parsing for sets of reliable terms, it can actually be relatively accurate. If I'm doing something like a laboratory report that's so discreet, so finite, and it's so finite with how many alternatives you have with the same concept, it works really well. When you start getting into things that are much more nuanced, you actually start to have a combination of technology with the expert humans to actually have confidence in the ultimate outcome.Now we do have some very sophisticated AI models. Like I'll give you an example. When you're looking at a medical record, usually metastatic status has just done a point of first but diagnosis in cancer care. So if the patient actually progressed and they made through there that they don't update the electronic medical record because they want to maintain what the starting point was when therapy was administered.But a biomedical researcher wants to know it at a point in time. So we have models that can literally read the record and bring back that status at any point in the time of disease progression. Now, would that work up to the grade of, say, for regulatory submission? No, but for a rapid analysis to pull back your question of interest and have it done in minutes, as opposed to weeks or months it works exceptionally well.Harry Glorikian: Understood. Understood. So now you and I both know that clinical trials, you know, are available only to a certain portion of the population really participate for  a whole bunch of reasons. And then if you go down to sort of, you know, equality or, or across, you know, the socioeconomic scale, it, it gets even, it gets pretty thin, right? You guys, I, I think you've been pushing around inequality and cancer care and you have this program called ERACE which I think stands for Engaging Research to Achieve Clinical Care Equality. So help me out here. What is that? Jeff Elton: So we are, as an organization we're super privileged to have a very, very diverse workforce. And you know, men, women all forms of background races, ethnicities, and we really value that. And we've tried very hard to build that in our scientific committee. And I think when the public discourse around kind of equity, diversity, inclusiveness came forward, and you know, as you know, Harry, this has been a unprecedented period of time for just about anything, any of us. I mean, COVID-19 and social issues. You know, things of that nature. It's, it's really been a very, very unprecedented time in terms of how we work and how we interact and the questions.Our organization and our scientists actually came forward to me and said, you know Jeff, we have a tremendous amount of data. We have partners like American Society of Clinical Oncology and some of the leading biopharmaceutical researchers in the world. And we've got technology, et cetera. We want relevance. We really want what to make contributions back and we believe that actually, we can do some research that no one else can do. And we can actually begin to deliver insights that no one has the capability to do. Would you kind of support us in doing that? And so we put together the ERACE program and it actually was named by a couple of our internal scientists.And the program actually now is being collaboratively done. We've done a couple of webinars, with you know, some of our partners and that's included, you know, folks from, whether it's AstraZeneca, Janssen, and BMS, et cetera. It's become something around, how can we rethink how research takes place and actually assure its representativeness for all groups, but particularly in specific diseases. It impacts different groups differently. And so can we make sure it reflects that? Would we be generating the evidence so that they can in fact be appropriate beneficiaries earlier? And a lot of this came from when we looked at aspects of diagnostic activity we could say that, you know, black American women have a higher incidence of triple negative breast cancer and a few other diseases. When we look at patterns of diagnosis and activity, unfortunately, the evidence that we even have is not substantially in the practice of what we're actually seeing sometimes when we begin reviewing our data. And so we began confederating through our own work. We now have actually set up research funding. So we actually now will fund researchers who come in the academic community. If they come up with research proposals that have to do with, you know, health related disparities, whether it's economically based, or if it's racial, ethnically based. Those questions. We've got an external review board on those proposals. We'll provide them data technology and financial support to get that research done. We're doing it with our own group and we're doing it collaboratively with our own kind of biopharma sponsor partners kind of as well. So for us right now, it's about confederating an ecosystem, it's about building it into the fabric about how research questions are framed, research is conducted, clinical trials are conducted, and then actually those insights put into clinical practice for the benefit of all those groups. And so, you know, it's even changing where we get our data from now. So it's, it's like an integral part of how of everything we do. Harry Glorikian: So you saw, I don't want to say an immediate benefit, fooking at it this way or bringing this on, but I mean, you must have seen within a short period of time, the benefit of, of, I don't want to say broadening the lens, but I can't think of a better way to frame it. Jeff Elton: We were surprised how quickly, whether it was academic groups or others, rallied around some of the concepts and the notions. And we were surprised how quickly we were able to make progress in some of our own research questions. And we were pleased and astonished, only in the best ways, that we saw industry and biomedical research, the whole biomedical community, attempting to integrate into their research and the questions that they asked actually different ways of approaching that.And in fact, it's probably one of the most heartening areas. You couldn't have legislated this as quickly as I believe leading industry biomedical innovators decided it was time to kind of change portions of the research model. And you made a, Harry, you made a statement earlier on that. It's not just about kind of us analyzing data. Sometimes bow you find that to broaden actual, say, clinical trial participation, I actually have to go to sites that historically didn't conduct clinical trials. I may need to have investigators that are trusted, because some of the populations we may want to interact with don't trust clinical research and have a long history about why they didn't trust clinical research.So you're changing a social paradigm. You're changing research locations and capacity and capability for that research. So we're now moving research capacity out into community settings in specific communities with this idea that we actually, we actually need to bring the infrastructure to the people and not assume again, that people want to kind of go to where the research historically was conducted because that wasn't working before, you know? Harry Glorikian: At some point, you turn the crank enough, you start to influence, you should be able to influence, you know, standard of care and all that stuff, because if you're missing data in different places, you've got to make sure that we fill these holes. Otherwise we're never going to be able to diagnose and then treat appropriately.Jeff Elton: Generate the evidence that supports actually doing that and do it on an accelerated basis, but also that it gets confidence for those decisions. Absolutely. That's part of our goal. Harry Glorikian: Yeah. So I want to jump back in time here and sort of go back to your your Healthcare Disrupted book. You know, I feel like, you know, we're on the same page because I think the message was, you know, pharma, devices, diagnostics, healthcare, they need to rethink their business model to respond to this digital transformation, you know, which is obviously something in my own heart. I've been sort of banging that drum for quite some time.In particular, you argued in the book that real-world data from EMRs, wearables, the Internet of Things could be combined to change how and where healthcare is delivered. Is there a way in which like Concert AI's mission reflects the message of your book? Can I make that leap?Jeff Elton: I appreciate the way you asked the question and I think if you said our principles and perspectives about that, we need to kind of focus on value and outcomes, and then we're going to be bringing insights, digital cloud, and a variety of other tools to underpin how we work and operate. Absolutely.And in fact, I think, you know, positively. I had a lot of engagement and did a lot of interviews, even as we were putting the book together, which took place over a couple of months ago, it was probably, you've done your own books. Whatever you think it's going to be, it's a lot longer. So I'll leave it at that. I have recovered from the process now, but I think we had a lot of engagement, whether it was with medical community, biopharma, leadership, community, et cetera. And I think that alignment is some of the alignment we have with our partners today. It's actually around some of the same principles.What I couldn't have predicted, in fact, I was a couple of years ago and this probably would have been towards the tail end of 2019, I was already starting to think about, okay, I've recovered from the first writing. How did I do? And what would I say now? And at the time I was beginning to say certain things seem to be taking shape slightly more slowly than I originally forecast, but then COVID-19 happened. And all of a sudden certain things that we kind of had thought about and kind of had put there actually accelerated. And in fact, I think, you know, out of adversity, you'd like to say we bring sources of strength we didn't know we would kind of be beneficiaries of. But out of that, you could argue this concept of say a decentralized trial activity.So we have, let me pick up, you know, I'm one company, but let me pick a parallel company that I have respect for, say, Medable as an example, and Michelle [Longmire] leads that company, it does a very nice job, but that's the idea. Everything could be done remotely. I can actually do a device cloud around the individual. I can do a data collection and run RCT-grade trial activity. Now that doesn't work super well in oncology, hematology, et cetera, where I'm, you know, I'm doing chemo infusion and I have to do very close surveillance, but that concept is an accelerated version and got broader adoption and actually was part of some of the COVID-19 kind of clinical studies and capability. And it's not going to revert back. So actually what happens is you find it has a level of efficiency, a level of effectiveness and a level of inclusiveness that wasn't available before, when it had to do facilities-based only. Now we ourselves now we're asked to accelerate, we bring technologies and integrate them into provider settings for doing retrospective analysis. But actually during that period, not only did we bring our clinical study design tools and use AI and ML for doing that, which led to, we've supported the restart of many oncology studies now, and actually the redesign of studies to be able to move into different settings that they never were in before.And actually now we're beginning to use some of our same approaches for running prospective studies, but from clinically only derived data sources. It's a very different paradigm about how you conduct clinical research. So when you think about this, there are unpredictable shocks, you know, which, you know, some of may have called Black Swan events or whatever you may ascribe to it, that actually are now consistent with everything we did. But actually accelerating it and in a weird way back on trajectory, if you will. But I think, yes, everything we're doing was informed by a lot of that seminal work and research and foundation about what worked in health system and didn't how are people being beneficiaries or not? How do we need to change how we do discovery translational clinical development? And we're very committed to doing that. Harry Glorikian: Yeah. I mean, it's interesting cause you almost answer my next two questions. I'm really hoping it doesn't slide backwards. That's one of my biggest fears is, you know, people like to revert back to what they were used to.Jeff Elton: But you know, maybe to encourage you and me. So one of the things, if you take a, let's take a look at a teleconsult. So during COVID-19, HHS opened up and allowed as a coded event, doing a digital teleconsult for kind of digital medicine, telemedicine, and that was put into place on an emergency basis by HHS. And then before the outgoing HHS had that, it's now made permanent. And it's now part of the code that actually will continue to actually be a reimbursable event for clinicians. That was actually super important during COVID-19. What's not that well known is, not only did that allow people to be seen, but hospital systems were really financially distressed because most of their work was informed by kind of, you know, elective procedures and things of that nature. And that couldn't take place. But the teleconsult became a very important part of their even having economic viability, which you can't underestimate the importance of that during a pandemic. Right. So now that's part of how we're going to work. My personal view is, now that people are using digitally screening tools, they have decentralized trials, some of the solutions that we're putting into place, AI-based, bringing RWE as part of a regulatory submission, I don't see anything going back. And the work we're doing is if we can start putting 30 to 50% time and cost improvements and add more evidence around a decision, more robustly than we did before, that's not going backwards at all.Harry Glorikian: Good. That's that makes me. I'm hoping that we're all right, because we've been saying this and beating this drum for quite some time.It's interesting, right? Because I don't think I've gotten over the whole writing thing because I've got a new book coming out in the fall. So you know, I, I couldn't help myself. I hope, you know, we. We're able to give the listeners sort of a view of where this whole world is changing, how data's changing it.I mean, I've had the pleasure of talking to people about digital twins and that sort of data. And I believe that this, we're gonna be able to make predictions, as you say off this data almost proactively. It's interesting because I do talk to some people who are in the field that look at me strange when I say that, but after working with different forms of data in different places for so long, I can see how you can look at things predictively and sort of, you know, decide what's, you know, see what's going to happen almost before it happens for the most part, if you have a big enough data set. Jeff Elton: So we do a lot of prediction thing in the AI and ML world. And we predict, you can actually be relatively accurate on who's going to adhere and not adhere. You can begin to look at the biological response to being placed on a new therapy and understand whether that response is kind of in a direction that, that patient's going to remain on that therapy, or you need to discontinue to be placed on a new therapy.And you're right. And in fact, some of these features…well, the question, we use it from generating insights to design and hopefully improve outcomes, et cetera. That's a rapid process. I mean, I've seen things in the last three years in setting up Concert AI that would have taken me a decade to have seen in previous methods. But we're still not as fast and as effective as we can be.And the very fact that I can in my digital laboratory, if you will, create AI/ML to predict whether that patient is going to be discontinued or continue on to that course of therapy. Some of that needs to be brought into confidence tools that can start to inform parts of practice as well. They're not ready for that. They have to ascend to that. But when you look at these, some of these, whether it's coming in as software, as a medical device, sets and solutions to augment, are going to add a huge, huge amount of utility. And you're finding a lot of interest, even biomedical innovators are looking for predictive tools, too, complement their medicines.And you know, we're doing a couple of things that would be definitely considered in a more confidential area around doing that right now. And I have to tell you I've been so pleased and it's just for me, it's so, so catalyzing of our energy to be brought into this, to see people willing to reshape the paradigm about how they do things that actually will reshape how medicine's delivered and care provided too. Harry Glorikian: Oh yeah. I mean, look, ideally, right, I think every physician wants to give the patient the optimal therapy. Not pick the wrong one and have to redo it again. But, but I think a lot of these tools are also gonna lend themselves to adjudication.Jeff Elton: Absolutely. Harry Glorikian: Right? And that is a huge paradigm shift for everybody to wrap their head around. And I think we're going to get pushback from some people, but I can't see how you don't end up there at some point. You can see where it's going. You know, what's going to work, here's the drug. And if it doesn't work, here's the data to show [why] it didn't work.Jeff Elton: Well, and actually and Harry, to your point, right now you're thinking about how payers authorized the treatment that's proposed by our clinician for super expensive medicines. Right? But if I'm an oncology, I can tell you right now that claims data as a single data source can't tell you much about whether that patient responds, whether they're being treated according to NCCN ASCO guidelines or not. So you're wondering what's the basis of that. Whereas I can actually look at the data and I can understand how that patient presents and I can see what's actually the intended treatment. And you can immediately say that perfectly makes sense, given how everything's matched up and I can continue to kind of say what that response is it consistent with what I would have hoped for placed in that patient on that specific treatment. So to your point, this is going to change all sorts of things.Harry Glorikian: I love it when it changes on that level, it just makes me all happy inside. So, Jeff, it was great catching up with you. I hope when this pandemic is open, we can get together in person and you know, have a beer. Maybe we'll even bring Arshad because I think he's been working in this whole data area with a number of companies for a while now. Jeff Elton: Yeah. Would love it.Harry Glorikian: Excellent. Jeff Elton: All right. Harry Glorikian: Thank you.Jeff Elton: Thank you too.Harry Glorikian: That's it for this week's show. You can find past episodes of MoneyBall Medicine at my website, glorikian.com, under the tab “Podcast.” And you can follow me on Twitter at hglorikian.  Thanks for listening, and we'll be back soon with our next interview. 

Hey Spoopers, it's time for the August Showdown! A Triple Threat for TV Terror Triumphancy: Brooklyn Nine-Nine "Halloween II" (S02E04; 2014) vs Family Matters "Stevil" (S08E07; 1996) vs Community "Epidemiology" (S02E06; 2010) Don't change that channel, because we're about to settle who has the best episode of Halloween TV out there. Is Brian's hopes of defending his belt with a dummy all a dream? Does Meg's show have 99 problems but a witch ain't one? Will they both refuse to be indoctrinated into the cult of Harmon by Steve? One thing is for sure Necco wafers are F tier candy. Tune in as three mutant horror nerds rip each other's guts out on the way to deciding who's favorite show reigns supreme! Find Us Online- Instagram: https://www.instagram.com/halloweenisforever/ Twitter: https://twitter.com/HallowForever Facebook: https://www.facebook.com/HalloweenIsForeverPod E-Mail: Halloweenisforeverpod@gmail.com

This episode should be a lovely walk through our various childhoods. Even though we start back in 1847, we will eventually get to your decade. Of course if you are younger than 30 then you are not going to qualify for retro anyway.Before we started recording, we raided the shop and laid out in chronological order a heap of product. Throughout the pod Phil and Barbara grab the occasional packet and reminisce.  As discussed in other episodes, the 1920's was an amazing decade of innovation and candy was a part of that incredible growth. As expected there are have been some candy casualties but there will be a lot of familiar names.Some questions answered along the way are, what does Necco stand for, what candy wrapper did Salvador Dali create and what is the oldest candy still in production.Another fun episode summed up beautifully by the sign-off thanks to Ryan Gosling. 

Welcome to the Instant Trivia podcast episode 157, where we ask the best trivia on the Internet. Welcome to the Instant Trivia podcast episode 157, where we ask the best trivia on the Internet. Round 1. Category: A Driving Tour 1: Drive by the cops when you put the pedal to the metal on most of these high-speed German highways. autobahns. 2: Krasnaya Ploshchad is the local name for this square you can drive by, but not across. Red Square. 3: High degree Freemasons know it can be hard to drive by this L.A. auditorium on Jefferson Blvd. on Oscar night. the Shrine Auditorium. 4: You'll reach the president's office in this country driving to the union buildings on Government Ave. in Pretoria. South Africa. 5: Drive down Obala Vojvode Stepe in this city and relive the street's most famous moment of June 28, 1914. Sarajevo. Round 2. Category: Necco Sweethearts 1: 2-letter word that precedes "mine", "good" and "true" on the hearts. be. 2: In 2001 a colon and right parenthesis were put together to create this design on a heart. happy/smiley face. 3: The pink hearts are cherry flavored, the green, lemon, and the yellow, this. banana. 4: In the 2001 mix there was the name of this goddess or planet. Venus. 5: Originally called Motto Hearts, the fact they're now called this will give you something to talk about. Conversation Hearts. Round 3. Category: Taken Literally 1: German combo of "car" and "road". Autobahn. 2: French: black beast; English: nemesis. a bête noir. 3: It's Spanish for "hand to hand". mano a mano. 4: Evidently, it's Latin for "from the first face". prima facie. 5: "Inquistion" contestants know its Portugese for "act of the faith". auto-da-fé. Round 4. Category: Journalists 1: Jason Robards played this Washington Post editor in "All the President's Men". Ben Bradlee. 2: This son of a "60 Minutes" correspondent was at ABC News for 15 years before joining Fox News in 2003. Chris Wallace. 3: "A Mighty Heart" is a 2003 biography of this slain Wall Street Journal reporter by his widow, Mariane. (Daniel) Pearl. 4: This Pulitzer winner gained fame reporting on My Lai and has written on Iraq for The New Yorker. (Seymour) Hersh. 5: Michael Kinsley is the founding editor of this "rocking" online publication. Slate. Round 5. Category: Geographic Cinema 1: 1979:"The blank Horror". Amityville. 2: 1957:"The Spirit of blank ". St. Louis. 3: 1987:"Born in blank ". East L.A.. 4: 1931:"Sidewalks of blank ". New York. 5: 1960:"Sunrise at blank ". Campobello. Thanks for listening! Come back tomorrow for more exciting trivia!

God loves you! God gives you a Valentine invitation - Be Mine! God expresses his love for us in many different ways, but the greatest demonstration of his love is that while we were yet sinners, Christ died for us. He became less so that he could fully demonstrate his love for us. Even though God is all-powerful, he became a man and bore our sin, so that we could spend eternity with him. He loves you! He wants you to be his; will you say yes to His invitation? https://www.youtube.com/embed/Xg7uFG6SsQk Welcome to Redemption Church in Plano Tx. It is crazy cold in Texas this weekend, but we are still gathering to do the 3 things – Everybody worships, everybody receives the Word of God, and everybody talks to God. My name is Chris Fluitt I am thankful for everyone in the room and everyone online. God Bless you all. Thank you for joining us this Valentine's day. Happy Valentine's Day I hope all of our couples have had a wonderful day together. God cares about your relationship. I was at the store the other day and found my way to a valentine's day aisle. There were lots of balloons, cards, and candies. Then I saw these little heart shape candies with writing on them… We have all seen them before right?  These are the candies that taste like they were surely made out of old chalk from your elementary school.  These candies are actually called “sweethearts conversation hearts” by a company called “Necco.” (New England Confectionary Company) Candies As I was thinking about how bad these candies tasted, I began to think what message would fit God's valentine toward you and me. Can you think of any of the messages that are written on these candies?  Some of them are really silly and I am not sure I could see it being God's valentine's message. Cutie PieLove bugHug mefirst kiss, kiss me, or let's kissUR Hot, TOO HotU ROCK Some get a little closer perhaps…Soul mateforeverI heart UMe & U But I think the message God has for us is one that Necco originally stamped on their candies when they started selling in 1902.  That message is… Be Mine. Be Mine God's message for you today is Be Mine.  This will also be his message tomorrow.  Be Mine is His message to you always. From beginning to end. Malachi 3:16-17 (NIV & NKJV)) Then those who feared the Lord talked with each other, and the Lord listened and heard. A scroll of remembrance was written in his presence concerning those who feared the Lord and honored his name.  "They shall be Mine," says the LORD of hosts, "On the day that I make them My jewels. And I will spare them As a man spares his own son who serves him." God speaks to a people who were outcasts… They had been disobedient. They had failed to walk in a relationship with God and had gotten themselves into so much trouble… and yet God sends them a message through the prophet Malachi.  God says “Be Mine.” Be Mine Be mine is a request. Be mine requires free will.  Love requires free will. God gives you an invitation today – be mine. God loves you and wants you to decide to be His. In scripture God calls you the apple of His eye. (Zech 2:8 Deut 32:10)Scripture declares that his love is as high and great as the heavens. (Psalm 103:11)Jesus says the numbers of hair on your head are numbered (Matthew 10:30)He rejoices over you with singing (Zeph 3:17) Over and over in scripture God has invited us – Be mine. But what happens when the love given is not received?  This is one of the great reoccurring concepts and themes in stories.  It is called unrequited love. Unrequited love is a love that is not reciprocated, even though reciprocation is desired. Any love that is not returned to the same degree it was given. Shakespeare, Hemingway, Dickens… Many great stories feature unrequited love. You can hardly read a book, watch a movie or tv show, or listen to a song without running into the theme of unrequited love.Phantom of the Opera,

Jacob Geller (YouTube video essayist) is traveling down the road known 99 Questions Boulevard. Jacob and I discuss what drives him to make content, what happens to unused video ideas, movies not to see during a childhood birthday party, and Necco wafers. 99Q Merch 99questionspod@gmail.com 99Q on Twitter --- Support this podcast: https://anchor.fm/99questions/support

Maybe we should have made this two episodes because it is a doozy! Jesper and Autumn cover a ton of tips and steps to launch your book, starting from 12 weeks out from your book release until 5 weeks after. After? Yes! Discover why there are actually steps to your book launch strategy that take place AFTER the actual release! Check out Publisher Rocket at https://amwritingfantasy--rocket.thrivecart.com/publisher-rocket/ *Note: This is an affiliate link and using it will help us out, but we're mainly an affiliate because we use and love Publisher Rocket ourselves. ❤️ Tune in for new episodes EVERY single Monday. SUPPORT THE AM WRITING FANTASY PODCAST! Please tell a fellow author about the show and visit us at Apple podcast and leave a rating and review. Join us at www.patreon.com/AmWritingFantasy. For as little as a dollar a month, you'll get awesome rewards and keep the Am Writing Fantasy podcast going. Read the full transcript below. (Please note that it's automatically generated and while the AI is super cool, it isn't perfect. There may be misspellings or incorrect words on occasion). Narrator (2s): You're listening to the Am Writing Fantasy podcast. In today's publishing landscape, you can reach fans all over the world. Query letters are a thing of the past. You don't even need a literary agent. There is nothing standing in the way of making a living from Writing Join two best selling authors who have self published more than 20 books between them. Now on to the show with your hosts, Autumn Birt and Jesper Schmidt. Jesper (30s): Hello, I am Jesper. Autumn (31s): And I'm Autumn. Jesper (31s): This is episode 72 of the Am Writing Fantasy podcast and the topic of today's episode is book launches, and Autumn and I am going to share how we handle the launches of our books. And uh, you can basically feel free to copy as many of the steps that you want so when we go through it. Autumn (54s): And definitely some tips on things I think we've tried in the past that you don't know if they're quite worth the effort anymore, but we'll get to those. Jesper (1m 3s): Yeah, yeah, for sure. Yeah, I mean, and, and I guess we could also say that there was a ton of ways you can do a book launches. We've put our list together based on all kinds of things that we've done throughout the years and that this is, this is a part of the, the master list that we arrived at. But uh, yeah, I will cover that step by step, uh, you know, in a, in a bit here. Autumn (1m 28s): Absolutely. So how are things over on your side of the Atlantic? Jesper (1m 36s): Well, well, to be honest, uh, it feels a bit tired today cause this morning was the first morning in quite a while where I had to get up early to take the kids to school. Autumn (1m 50s): Oh that's right. Jesper (1m 52s): Because why would there have been like everybody else in shelf quarantine for a long while now. Uh, but uh, he, in Denmark, things are slowly starting to return to normal, well, I guess normal in quotation marks, but the, the Corvette 19 pandemic a lot to everything down as we all know by now. But we are, we've started lifting. It's like we hear. So it happens to the stages here in, in, in Denmark. Um, and a, one of the first stages is to get kids back to school so that parents can start working again. Jesper (2m 25s): Um, and, well actually our kids were supposed to go back to school a week ago, uh, but we kept them at home last week because we were, first of all, we as parents felt that it was a bit soon that they began opening things up again. And uh, we also had a conversation with the kid's at the lunch table, um, last week and asked them how they felt about, and they both said that they did not quite feel safe, so we decided together with them that they will stay at home another week. Jesper (3m 0s): So, so that's what we did. So they started today. While there are friends started a week ago. Autumn (3m 7s): That's some peer pressure, so they knew their friends were back in as everything waited a week and that they, you know, life, nothing blew up. I guess it's a good that they decided that they felt safe enough to go back to school. Jesper (3m 20s): Well, yeah, we asked them all over the weekend how they felt about it in that they both said it well, the youngest said, yeah, I'm fine, I want to go back. But the oldest, it was more like, yeah, I'm still not quite feel comfortable with it, but on the other hand and you know, we'd talk to him and it's a sort of, I had a conversation around how you probably never feel entirely comfortable because you don't know what's what it is. Right. Right. You don't know what's going to happen when you get there and, and all those things. So, uh, but they went to school today and when I picked them up, they were both really happy, uh, that they went and so everything went well. Jesper (3m 56s): But a, but actually also I wanted to misspeaking of Corona virus. Right. Uh, these days I would really, really, really prefer to stay far, far away from hospitals. Uh, but unfortunately actually have to take my youngest son there the other day. Oh, no. Yeah, he was driving his scooter outside. Um, and, uh, well he basically just, he fell, landed with his, uh, entire body with, on, on his elbow. Jesper (4m 28s): So we were quite worried at his arm was broken. So we have to go to the hospital in the middle of these Corona virus days, which I really would like not answer to. Yeah. And I guess they were really busy. They're, because we spent the entire evening there, something like three, four hours to get to his shoulder or elbow. I meant, uh, x-rayed and looked over. But luckily enough, it was not broken up this morning. A couple of days later, he, he, you know, as I said, he went to school, he had no pains. Jesper (5m 2s): Okay. So everything seems okay now. But yeah, this has been a bit of an interesting week. That's crazy. Well, I'm glad he's fine. That's not there. They keep saying now this is not the time to do something stupid and get yourself hurt. So well, I mean is it really don't want to go to the hospital, but, but what can you do a very true, yeah. And how is a everything on your side? Jesper (5m 33s): We are fine. I finished my built in storage benches. We have cushions on order and so the major goals and major building projects of my little cabin are done and you know, I wanted to like finish it up over the weekend and then it was going to be, um, obviously we are working on a character development course is going to do some computers stuff, but it was going to be like I wanted to have that moment where you just stop and the sun shines in the window. Do you have a thought? Oh you know, it looks like it has done two and a half months of building and getting settled and I can finally put stuff away and get rid of the sawdust on the floor where I'm also living in such a filtering in place. Jesper (6m 17s): And instead it was probably the more realistic version of two and a half months of building and living and sheltering and pandemic and want to adapt. Autumn (6m 29s): So you can see why I think it finally hit me a nice still. I mean I feel very content and kind of calm, which is still lovely. I don't feel like there's this huge pressure to go, I got to do something, the show results. But I definitely still have that kind of like, yeah, I'm not in slow mode but I'm not in like let's get stuffed on it. I'm not, I'm not under a total drive. I'm going to sitting back on my heels going, yeah, I could have a beer. That's where I'm at. Autumn (6m 59s): But I think, um, I think as I recover and you know, speaking every time I'd used, you know, we have skill cells and compound miters and all these things we've been using in jigsaw calls and every time I go to cut something, I always had that moment of be careful. Don't do something stupid. You don't want to go to the hospital. Right. Yeah, exactly. Yeah. Yeah. That's it. We'll have those moments. But I've seen, I have, um, my right knuckle has been a little bit sore and I actually have a brace on my left arm cause I've a little bit of a, like a tennis elbow going on from something in my right shoulder hurts. Autumn (7m 33s): It's like a joke. I can't open the door with my right arm and I can't pick up my teacup with the left arm and I'm like, that heals because I've been in, I did go through my upper birthday. I'm a year older officially, so I'm not a known for a spring chicken. I'm once my body catches up so she loves me a year younger, once a week once everything catches up and I'm feel a little bit better and I can just enjoy being very physically fit, I will probably just be a little bit happier and then I'll be so excited. I'll have my moment in the sun of Yes. Autumn (8m 5s): I'll sit on a picnic table by the stream and the waterfall and I'll be like, this is good, this is good. But right now having a blankie, it's a good that you're going to hold it all the building stuff that, I mean you don't want me in chats of billing anything unless it's like a building, but I can build a world, but I can not build a cabin. We go on the internet with the Am Writing Fantasy Podcast. Autumn (8m 36s): So that was quite a few good post in the Facebook group over the past few days. I don't know if you noticed that to know. I, my husband recently pointed out, he's like, I do this every day. He has been doing a climate log and actually weather forecasting everyday and observations about the woods. He's like, and you don't even go look at it. I'm like, no, because it's on Facebook. I have been on a Facebook diet, not on purpose, just I had to cut something out for a little bit and I've got that out. Right, right. I appreciate you and taking care of the group because I know it would, it would be a dead plant if I was in my household right now a little bit. Jesper (9m 15s): Um, Luke is good at taking care of things as well for you, but there was a quite a few good, but I just picked a few here at just to mention because I thought they were really good. Um, so Linda posted in the Facebook group, uh, a picture of the For heart horseman of procrastination. I thought that was it. Autumn (9m 37s): That's great. Uh, and, uh, Jesper (9m 41s): there was also Jason, he finished his first draft of it for nearly a 150,000 words. Autumn (9m 47s): Oh gosh, yes. We rolled on progress forever. I missed that. I have to go find his post now and say congratulations. Jesper (9m 55s): Yeah, it's a so, so, so, so well done. So a, yeah, we just wanted to call you out Jason thing and congratulating you on, on that. Um, and we also have a Tony Join quite recently, I think it was only like two or three days, uh, ago, uh, since I let her in. Uh, well, of course when you listen to this, we were pre recording it at an event. So you have been a part of the group for a while by the time we listen to this town you, but uh, but she, um, she showed some interesting creating a shared world. Jesper (10m 28s): Uh, so she was asking if somebody was interested in that, so that, that was pretty cool. That's really cool. Yeah. And at the quite similar as well. Alexandra's uh, he was looking for a coach, author, so that was also quite nice. And I don't know, maybe he should check out Episode 58 of the podcasts because we actually talked about how to find a co author or a writing partner in that Episode. So that was 58 but a lot of good, interesting conversations happening in the Facebook group. Jesper (10m 60s): So a Yeti your list know if you haven't checked it are already and how we should show you can so just search for Am Writing Fantasy in the group section of Facebook and uh, you will find us. Autumn (11m 10s): Yeah, I'm excited. I'm excited to get back into it because it's always so dynamic and interesting. It's just crazy to hear what's been going on. And like I haven't been on for a few days, I swear it's not in a full week, so that's just fantastic. Yeah, absolutely. I did like the fact though that we are, you know, at least people do track us down. Um, occasionally if there outside of Facebook. But I know Audrey sent us an email, she just recently joined the Writing list to Writing Tim list. And she had said that her biggest hurdle was in finishing a novella. Autumn (11m 44s): And she was writing by inspiration where he got into a good conversation emailing back and forth about that, about, you know, how Writing basically I just read this great metaphor. We're writing is a muscle. It's sort of like, you know, it's something that you need to work on every day, not just because it's somebody who should work on everyday and then you build your schedule. It's like muscle memory. It's you build your stamina. So I just thought, yeah, that's my new metaphor and my new kick and the butt to my re my, my physical construction is done. Autumn (12m 15s): So now I've got to get back to a word construction. Yeah. Yeah. And it's, it's, it's important to a, to keep doing it. Um, especially that the part about when you don't really feel like Writing that, but you still put the pot and the chair and go get it done. Jesper (12m 32s): Right. Because, uh, you can always edit it later, but, but do the thing about all, because there are some habits stuff and this as well, you know, if you can train yourself into the habit of this is what I do, even if it's just like a 20 minutes or 15 minutes early in the morning before you have to go off to the day job or whatever. But getting into a habit of doing it, that really helps in the long run. Definitely. Jesper (13m 3s): So a book launches, Oh this is something that a, a lot of people talk about quite often. Autumn (13m 12s): Well, there are important, I know, and it's, I think a lot of people take two views of book launches and the one is that it is a life or death of a Book. You need to launch big and launched loud and get a ton of sales. And that's how you do it. And then I think there's other people who think it's a marathon and you launch the book and it should be celebrated because that was a big deal. Jesper (13m 34s): But that is not the, Autumn (13m 36s): and by far a finishing a book, you need to do a lot of marketing plans after that. But the book launches kind of like the first big marketing. Jesper (13m 47s): Yeah, I agree. Of course its always nice to see if you can get a good book launch going so that you get an influx of cast. So when you release a new book that's so of course nice. But uh, I I I as well will you often hear is all the stories about the amazing book launches have a, I don't know what 50 a hundred K on whatever it is. People, I mean yeah fine. But I really don't think that that's a good way of looking at it. It's, it's, it's good to Launch wants the book well and of course you should put thought into it and do the best that you can but its, it is really not, it's not the end all. Jesper (14m 27s): If, if the Launch is in the best one, it could be. Autumn (14m 30s): No. But it is exciting if it does well enough and you get on the hot new release list on Amazon or even on the other one's bestseller. Those are exciting goals. But absolutely just because you don't get one, does it mean your book is not going to do well or sell a ton over its life? Jesper (14m 47s): No. So basically as I said up at the top of episode, we've put together a Launch process that we basically are more or less use, uh, for launching all of our books. And that's what we want it to share here with the listeners today. Um, we sometimes we tweak a few of the steps here and they are a bit of course a, I think that should be the method of this episode as well so that basically people listening take from it what you can and what you want and ignore it. Jesper (15m 18s): A rest. Right. And maybe maybe we are going to mention a few things she ended, it inspires you to do something that you hadn't thought about. And if we do that then I think that's a success enough for this episode. Sounds good to me. And I have a good, good caveat or this is what, how we were sharing. Yeah. So basically the way we do it is that we have an hour process divided into the big book launch starting 12 weeks ahead of launch and stopping five weeks after the launch. Jesper (15m 51s): So you got to be the one to explain time Yes it'll be a a, I think this probably a few people are scratching their head saying but its a book launch. What do you have something that you are doing something about your Book lunch five weeks later. So this will be absolutely, but I think it will make sense once we go through all these different faces. Probably the easiest way to do this to also keep some structure in the conversation would be to take them by weeks. So basically saying okay a block first block being 12 weeks ahead of Launch do this and do that 10 weeks ahead of Launch do this and do that and so forth. Jesper (16m 28s): And then we moved down the list until we get all the way down to five weeks after the launch. So I think that's the way that will keep some structured in place in a framework around in the conversation today. Sounds good. So Yes all right, 12 weeks prior to Launch you wanna start us off Yes so when we are 12 weeks before the launch, the you still have quite some good, you know, time your, you're willing to advance here. Jesper (16m 58s): So this is a good time to reach out to some relevant influences. So this could be maybe bloggers or YouTube burgers or podcasters, but the main thing is that their audience needs to match your readers. So for example, it would make no sense to reach out to us asking to be interviewed on the Am Writing Fantasy podcasts about a thrill, a book that you have coming up, for example. It makes no sense. No, this is not the audience. Jesper (17m 29s): Also, the focus of this podcast is to talk about writing and marketing for authors. It's not for readers. So you need to keep that in mind and try to find some sort of blogger or YouTube or a podcast or whatever it may be, who's a normal content is aligned with what your readers are watching or listening to or whatever it may be. Um, but at the same time, it's also not worth trying to get on to a hundred different podcasts Your or something like that. Jesper (18m 3s): It was just Yes that stopped by fucking making a list of like 15 mid range influences because the top, the top influencers, it's impossible to get on their podcast without invitations and the very low level once you might be very easy to get on the podcast, but the other hand you're not going to get out of it because the, they are low range, 50 in mid range influence. That's a pretty good to start with. And um, and then you, you go from there. Jesper (18m 35s): Um, yeah. Autumn (18m 37s): No I think that's pretty good. Yeah, I think so too. I think it's important to remember that even though your reaching out to influencers by 12 weeks prior, you should be, I mean hopefully by now you've got your book cover. I like it in the book cover as well. I'm still writing a lot of authors due now because one is inspirational but you can start sharing social posts, trying to build your audience and keeping it up to date. So you 12 weeks out you should have your book cover and even if you're not sharing it, even you have for doing teasers, you should be doing some posts on social media. Autumn (19m 9s): So generating, you know, getting people interested, letting people know about your book, what's coming out. Some of the world building your character is a, if you have a blog, these are the things that you should be doing right now to make sure that they are kind of getting on the vibe. I mean I remember, I know I've recently said this to someone that book launches used to be, you know, publishers would need a year to year and a half to generate all this stuff and the excitement about launching a book. But I think just like reader's are kind of expecting book's to be like coming out every month, which is probably not possible. Autumn (19m 42s): But there's also, it's everything's more of a flash in the pan. And I think the lunch strategy, I think that's why we started at 12 weeks out is because if you do it too soon, six months before you publish, people are maybe a little less enthusiastic. It's kind of good to start building up that energy, you know, three months before you launched because that's more the timeframe for us to get enough people in your resources together and get people excited. Jesper (20m 10s): Yeah, absolutely. And this is also then at the time where you upload your book to two different, uh, online retailers. So like Amazon and, and wherever else you want to tell you a book. Um, and at this point you are not, uh, which will make sense in, in, in a moment, but at this point you are not uploading the final version of the book. So this is like the, probably the, the edited version, I think at this point. That sort of leads to what we do. And so from our view of it is done but its not gonna be the final version. Jesper (20m 44s): We'll get back to that. So you have uploaded there and then there was a whole debate that one can have around should you do pre-orders or should you not do preorders and there are long debates and views about is it better or worse for you, your Amazon author rankings if you do pre-orders or not and all of that. And basically we sort of circled when that whole conversation by saying because we have a 12 week slow burning building anticipation process in place yet we are doing preorders. Jesper (21m 17s): Yes. And basically what are we saying is I don't care if it hurts the author ranking doing preorders who cares? Uh, I don't, so we are just building as a low anticipation over 12 weeks and hopefully uh, once we get down to the list, you, you will see how the stepping stones leads to some excitement. Autumn (21m 37s): Yes. And a big tip that I never thought about until, I don't know it was probably, it's been a year or so now, but I never thought of it. When you upload this draft version or nearly finished version, you don't have to upload your final cover. So if you are planning something like a cover reveal or something later, you can do a placeholder image of just about, you know it, it should be something I like. I have a couple of, yeah, it should be a, I have a little scrap one that looks like an old antique book cover and so you can just do that with your title and upload that so that if you do have a big cover reveal something later, you can upload your fake version, your holding version on good reads on Amazon and your distributors is drafted digital Smashwords so you know, keep that in mind. Autumn (22m 25s): If you want to be clever and do a big reveal later. You don't have to have the final version revealed to the public quite yet. That's such a good point of view just before but also 12 weeks ahead of launch. I wanted Jesper (22m 40s): to say a few words about email, newsletter squash, but just before I get there, before I forget, Please if you are reaching out two podcasts as a speaking as a podcaster, could you please listen to a bit to those people's, uh, episodes before you reach out to them to understand what is this kind of show and at least do a bit of your own research to find out why am I a good match for their audience and what they normally do. Because, for example, on our podcast yet, we do not take pictures for people to come onto the podcast. Jesper (23m 14s): We only invite people to come on AM. So once in a while, as you know, about once a month we'll have a guest on, but those are the only people that we have contacted because we want it to have a conversation with them. So sending pictures to people like us in a, I'm just using us an example here, but it's not gonna work. If you're trying to find 15 mid range influencers and you want to get on a podcast and you will never listen to it, even a single one of the episodes and you don't understand that this is not how they, they, they maybe they don't even do interviews at all. Jesper (23m 48s): Right? So you just wasting your time. Right. So please do that. A bit of research before you start reaching out to people is so annoying and getting emails from people who clearly don't know what they are, what the podcast is about, and then they're making pictures for something that makes absolutely no sense. It's so unhealthy Autumn (24m 5s): that I totally agree. Even with audience, somebody might look at ours and like, Oh, Fantasy I'm going to talk about a Fantasy book, but we're targeting Fantasy authors, not readers. So we do make sure you're not wasting your time and effort, um, Jesper (24m 19s): bothering someone who you're not even the right target audience. Yeah. Okay. So let me move on to newsletter swaps. This is basically where your reaching out to another author saying, okay, can you feed your, my book in your newsletter? And then I will feature in your book, in my newsletter we talked about that on past Episode as well. Um, here I have to say that for Autumn and myself we don't really use email newsletter swaps. And the reason for that is when we are publishing out our books, you hear that I don't like featuring another author's book in our email unless I've read it and I just don't feel comfortable with doing that. Jesper (25m 4s): Um, but if you do do newsletter swaps and if you do like to do that then uh, basically this, uh, 12 weeks prior to Launch is the, its a good time to get that organized. Find out who you want to do newsletter swaps with and a yeah and get yourself organized. Know why you still have a quite a while yet. And there are a lot of good places as a, in my private, my, my Writing individually last, I have done them in the past. So Autumn (25m 32s): yeah, there are good Facebook groups. There's a story origins, which has a fantastic newsletter swap area and BookFunnel. It's more for group giveaways but sometimes you can find some swaps through there. So those are the two of them are good places to look. Right. Jesper (25m 45s): And keep it John or a specific same as looking at influencers. Right. Good. So I think we can move on to the next Am bracket here. Which system 10 weeks ahead of launch. Absolutely. So, Autumn (26m 1s): and I was going to say, so we've already talked about reaching out to people and what are the steps to reaching out and I think we might've might have mentioned, should have mentioned this sooner, but you could mention it here. It's, you should develop a media kit for your book. So it sounds so professional, but this is a great way of AM sending people. So if you are reaching out to influencers, especially instead of sending them a bulk load of material, especially if you happened to have a website, put up media kit and have everything, some blurbs, some excerpts, some images, uh, you know, all of the information, the way that it's going to be released. Autumn (26m 37s): Is it going to be on sale? Are you going to have some reviews? Do you have some earlier reviews? Put it, all of that on some websites or a download or something and be able to direct people to it. It will save you so much time and money. Just just do that and have it ready to go by the time you either start contacting people are definitely by 10 weeks out. Jesper (26m 58s): Oh yeah. And then this is also a good time once you are updating your website anyway, so put you a book on to your website and make links to those preorders everywhere that you have the book for sale. And of course use affiliate links when you are on your own website. You are well within the terms of service from, for example, Amazon that you allow us to take an Amazon affiliate link and put on your own website to your own Book so that if people buy your book through your own website, you are not only get the royalties For from the book, but you are also getting affiliate income royalties. Jesper (27m 37s): So there's no reason not to do that. So make sure that that's what you do on your website. Autumn (27m 41s): Yes. And a little tip there. A, Amazon's not the only one with affiliate links. Even Google has affiliate links now. So if you have books on Google play Yes, it will make sure that you get them from each of your places and it really make a difference. And so as you're setting up all of this information, a do a preorder alert for a BookBub anyway, this is a good time. You know, make sure your book is up there in places where people are going to start seeing it in that they know that it's going to be alert. You know, I'm on Smashwords and I can also do alerts. Autumn (28m 11s): They're saying, Hey, new book's coming. You could preorder it, Jesper (28m 15s): let people know. Yeah. And there's a few more things to set up as well here. 10 weeks ahead of launch. So you should also get it on to, well, I'm saying book funnel now. I guess you could use other things, but honestly BookFunnel is just as a such a cheap, an amazing service that there was no reason not to use it. So you get, you get, the book's set up on AM on BookFunnel. So this is basically going to be your ad copy or the act also means advanced readers copy. Jesper (28m 46s): So this is basically the, the, the copy that you are going to ask you, a bunch of readers to read ahead of the actual launch that we're going to come back to that in a minute. But you upload that here, uh, to book funnel. And then you also add the Book on good reads if you have a profile there. Yes. Oh yeah. Yeah. And I would also, at this point in time, I will also start booking promotional sluts on different promotional sites, ah, for the launch week. Jesper (29m 16s): Now that you are still ahead of time, so are, you should be able to snatch up those, uh, those times slots. Autumn (29m 24s): And to me this is a good reason to do the preorder is because by having a preorder, you have a link and you can go ahead and book those promotions. If you're not doing a preorder, you can't do that until the book is live. Uh, it is just, yeah, you know that you're scrambling to try to get any last minute slots. And there's Jesper (29m 42s): only like, there's only so many advertisers who will do something for a book launch. Where do you have no reviews and they're basically standing on other books you have out in your overall review as an author. So you want to show, you want to make sure that you got in with them as soon as you can. So 10 weeks. That was a good time for that. Yeah, indeed. So do we have more on this or should we move on to nine weeks ahead? I think that's a good, that's good. Jesper (30m 12s): At 10 weeks, if you, if you said you were in building your media kit, still you've got plenty to do. Yeah. Well that was a, nobody set that book. Launches should be easy. You know, your running a publishing business and you're stinking a home, you're and a half a book launch into three to three months. You're gonna be on your toes. You thought you're a busy writing, wait till you trying to launch something while there is more work. Anything that you might think, at least if in my view if you want to do it right, but that's what we are. Jesper (30m 42s): That's what we were going through here. Yes so nine weeks ahead of Launch. So now, um, and this one, this first one that I'm going to mention that this is not vital at all. It's completely optional basically. But if you want, you can create a book trailer at this point or a, some sort of video promoting the book. If it's not directly a book trailer, then it could be something else. It could be a video with some of the world building in it or a something related to the Book. Um, this is optional, but why I have it on here, it's not because book trailers or videos like this is not going to move a lot of book sales at all. Jesper (31m 20s): But why I'm mentioning it is because it's quite nice to work with on Facebook ads because you can then retarget a, when you can set for Facebook to say, okay, everybody who watches at least a 50% of this video, I want to retalk it. And then you can use that as an audience once you get down to the day where the book goes live and retarget all of those people with, okay, the book is now out there. That's good to know that that's, that's quite a nice thing to do. Jesper (31m 52s): Um, and that, that's more the benefit of the book trailer than anything else. It's not the portrayal itself, but it goes without saying. Obviously if you want to do this, it has to look professional. If it's like a subpar, a video that you upload, nobody's gonna think it's interesting. Okay. So there was that and it's, it's not easy to do. So it's something to consider. It is I still once a book trailer for my own books and have it done it yet because I really want something high end. Jesper (32m 24s): No. Ken burns pictures panning to the left or right. I can't do it. So, um, I actually, I actually did one. Yeah, I did it. It's actually, it's on the Am Writing Fantasy YouTube channel. So if anybody's interested, interesting. You can go on there. But this is, so, this is like the do it yourself. The book trailer. Uh, I think it's okay. It's not the best top quality professional stuff, but I think it's okay. But I'll leave it for the listeners two jobs so you, you can let me know, just tweet me or something. Jesper (32m 56s): Once you watch it, you know what you think. But, but there was one day that people can look at it, see what it looks like if they want. Autumn (33m 2s): Yeah. But okay, so it still it nine weeks prior to the Launch I'm going to go and look at this now cause I don't think I have seen it there. So you have it. I don't think so. I've got to go look anyway, since we were off of that, it was a time if you are going to do cover reveals or a book title review or anything big, it's time to make sure that you're getting those scheduled at nine weeks out. One of the things I will say that you might, you know, book cover reveals are there used to be a big Facebook parties and things like that. And there, there, okay you gather a whole bunch of authors together and you'd maybe all give away free books or you do something and there's still events like that, but they become, instead of like hundreds of people, they've become a lot more cozy. Autumn (33m 47s): Often you'll see almost like it's like an author's you invited and just a few readers, even the big ones. So you know, if you can narrow your sites down, you get maybe 20 or 30 readers. That's exciting. It's good enough. But you'll have to decide if it's worth it. And I'd almost say the same thing. Booking blog Torres, this is something that you would do about it now. And as sort of the same thing, blogs are kind of fading. It's video as much more important. So if you had to choose between like a cover reveal party, Book tours or approaching influencers, go for the influencers. Autumn (34m 21s): Go for the video of the podcast format over going on Facebook and having something going on there. Jesper (34m 29s): Yeah, I would agree with that. Um, and I think as well for the cover reveal indeed, I mean if you go back and read some old blogpost on the internet and whatnot, you will see that it's being hyped a lot and I think it worked quite well as a strategy a while back. But I don't think you can get you get nuts getting much mileage from cover reveals to today. But the reason that we still do the cover reveal and uh, at this point in time, nine weeks out is basically only because it gives you another excuse to email your readers about the book coming out there. Jesper (35m 7s): There's a limit to how many times you can email them to say, Hey, the book is coming out now it's nine weeks and now its eight weeks and now it makes, it gets boring after awhile. And so this just gives you an excuse to email them again and remind them that the book is coming out and then you give them the cover as a cover reveal in that email. That's basically all I will. I mean, you can post it on social media as well. Why not? While you were at it, it's another reason to do a good book or a post on social media and Instagram. Yeah, yeah, exactly. So, so do that. But, but it's not that the cover reveal will assault all of sudden turn it into a load of the pre-orders or something, but not at all. Jesper (35m 43s): But, but it's, it's just a small building blood in the building. Anticipation castle that remit creating here. Yes. And don't forget though, if you do the cover reveal and you put up a temporary holding spot for your book on Amazon to go and AM put up your Real cover before it's too long, but it might be a good idea. Yeah. Yeah. But this is also then nine weeks out is also at a time where I will then set up this arch team. So basically you our advanced readers team, and this is pretty simple in the sense that you send out an email to your email list and you explain to them that you are looking for our team members and make sure that they understand what that means in the sense of what is it that you are expecting from them. Jesper (36m 29s): So you are going to give them a free book, a of this upcoming novel, um, and you are going to give them the opportunity to read it for free. And it's a, it's, it's been through your editor already. So it's the, from your point of view is the final version or we all know how typos getting past everybody. So they are a job in return for getting to read this book for free. The job is to learn to let you know every time they see a typo or out or if something or as well is unclear in the explanations or in the text or whatever, then they should also let you know. Jesper (37m 6s): But make sure that they understand that this is what they need to do. And also let them know by what date you need the feedback. And that is not even their most important role. That's an important role. But really the key wonderful thing about having this arc team comes on lunch day. But that is part of the agreement Yes uh, we can have come back to you exactly. Well save that for the lunch day. Yeah. Okay. So that was nine weeks. Jesper (37m 37s): 10 so we move into seven weeks ahead of launch. So you can see sometimes we're skipping two weeks. They're, it is not an error, it's on purpose. It's just because then you have enough time to go through all these steps. Right. So it's not because we can't a, we do math while we probably can't do that either. But that's not the reason because we figured you need a break for a week eight and you probably had a bit of homework to catch up on to get ready for week seven. Yeah, exactly. So seven to seven weeks ahead of launch. Jesper (38m 7s): There's not too much here. Be honest. It's really going to get in touch with your arch team, making sure that you know everyone is up to speed, that they have gotten the book. If you've sent it out by now, it's always a toss up. It depends on how long your book is. You want it to be pretty close to your Launch day that they are finishing. It is, but you don't want it. You know, if you don't want to have to have finished it a month before and then by a long time launch day comes, they're like, Oh right, I'm supposed to do something else. You want them to be engaged and excited. Jesper (38m 39s): So I know when I do mine, AM sent out my Launch team Book it's within the last month or so. It might be a little early to send it out now, but it depends on your book and who you have recruited and also how many people you have recruited. It's good to good to have enough people. You know, there is nothing wrong with having a hundred people who want to read your book and will help you out on lunch day. But you also have to figure is that too many of you have to decide what you need for your group. Jesper (39m 10s): Yeah, I think that that part depends a lot on what it is that you are asking for. If your asking for content feedback, then hundreds of people is too much. It's gotta take you forever to go through all of that content. But I mean, I don't mind when we send it out because we're, the only thing we asking for is typos for them to tell us the type of it. So I don't mind giving out 200 fee out copies. I don't mind at all. If 200 people can look through four and try to hunt for typos, they're going to catch probably 90% 99% of of the hours that are still there. Jesper (39m 44s): And then you should be pretty clean after that. So, but the other thing as well as I wanted to mention by reaching out to you as a team here is again you were hunting for a bit of content that you can use in emails to read us again so you could, the arc team members probably haven't read the entire book by now, but at least they've been part partly through it at this point. There should at least, and so you can ask them to share some of their favorite quotes from so far with you because those quotes then again gives you an excuse to email your readers. Jesper (40m 17s): Again, reminding them that they book is coming and giving them some of the quotes and you can basically tell them that these are the favorite quotes from the advanced reader team that they picked out for you. Just to tell them where it came from, that it's not something that you pulled out and because it also makes it more, well, it humanizes the process, right? It's not like, Oh, I picked the 10 quotes so I could send them to you, but it's rather like, no, I had a conversation with the art team. They liked these. So I just wanted to pass them onto you guys as well. Jesper (40m 47s): Right. So that makes sense. And of course made sure to provide the link to the preorder in that email as well. So those who haven't pick up the book yet and do so. And you couldn't repeat the whole process on social media as well. Of course. Absolutely. And also a good tip too is if this is a book on a series a, it doesn't hurt to make sure that you have any of the previous books. You can have those on sale right now as well. So you might probably have one to two already get those scheduled. Maybe do some promotional advertising with those. Jesper (41m 19s): But it's also good to, you know, get some funnels, some new readers into your series. If this is going to be another book in the same series. So if you want to get that stuff and make sure that you have that all going okay, so that wasn't much. So now you're not going to get two weeks' break. How are you going to get a one week? Break it down. Yeah, six weeks ahead of Launch. So here, this is the time to do something a bit different as well is that it's not unique in the sense that is not something that you never heard about before, but it's basically like an exclusive bonus. Jesper (41m 54s): So you set it up as a release, a contest. Um, there was a million ways you could do this. Um, but basically the, the, the main idea of this is of course that you are going to create a deadline, meaning that people need to take action now because if they don't, they're going to miss out. That's what you were playing on here basically to get people to preorder the Book because if you don't, you are going to miss out on this very awesome bonus that you can't get and you can only get this bonus here and now. Jesper (42m 25s): So once the bonus goes away, it's gone forever. So this has to be something that you are creating specifically for this book launch and that you are not going to offer anywhere else afterwards. So you create something and you create an opt in form for it, meaning that people, we'll have to deliver that email address to you so that you can communicate with them. And then of course the idea is that on one hand they should be more than willing to give you their email address because they are showing interest in the a bonus here that you are offering. Jesper (42m 56s): But on the other hand, it then gives you the possibility to email them and not only tell them about the bonus and who you want it if it's like a contest or if everybody gets it. Then of course later on your you have to be able to email them with the actual bonus itself. Uh, but it also gives you the possibility to email these people wants to book launches and tell them, okay, it's now available, which is quite nice. Yes, definitely a very good, definitely a good way to have that on your mailing list as well as get some more excitement going. Jesper (43m 31s): Yes, and I should also mention in terms of ideas for what can you do as an exclusive bonus later this year, later in 2020 a Autumn and I should be releasing in a free course for you. And in that course that will actually be some ideas about this particular point about how you can run contests, but also what kind of ideas could you tell? What kind of things could you offer as a price? But the main point here for right now that I want you to take away is please, please, please help yourself by making sure it's something that you can deliver electronically. Jesper (44m 10s): You don't want to be shipping something now, it's, I mean, maybe if you run one free book somewhere as a grand prize, but you don't want to do that for a whole bunch of people. You, you know, and it's much more exciting if everyone at least skits one thing, even if there was a grand grand prize, and I do, you want to make sure that you make it very clear in your rules that it has nothing to do with reviews. I, Amazon has very strict rules that you cannot buy. Give away is nothing can be done. You can never give a reviewer a prize or a payment. Jesper (44m 43s): So make sure it's clear that it is literally for buying the book and supporting you, uh, but never give anyone anything for, I'm actually leaving a review other than the thank you because everything else, if Amazon finds out you were in touch, Oh you're a, you're at the Crick without a paddle. But it does say, yeah, that's correct that, but it even goes further than that because actually you cannot also run an exclusive bonus where your demanding people to buy the book either. That's not a lot. Jesper (45m 13s): That's very true. So the only thing you can do is you can, this is what we're going to talk about this free course later in the year. Once we release it, then we're going to talk you through exactly how to do this. But the main idea is that you can say your chances of winning is significantly higher if you buy the book, which means that you can tell them, for example, so two, win this price. You need to tell me the first word in chapter 28 those are the things you can guess, you can say. Jesper (45m 44s): I think it's a fine Maybe. Maybe you are wrong, maybe a REIT, but if you buy the book you probably have a better chance of winning. So that's how you can do it. But you cannot force them to buy the book, but it cannot be like you can only enter this contest if you're by the book. That's not allowed right there. Good. So we should be clear about that. But we got to explain that more in the course of that. Yes, yes. Let's move on. Okay. Oh, where, where are we? Where are we still in six weeks? Yes. If you have more for that bracket. Otherwise we can move on to five. Jesper (46m 15s): I think we're on five. I think we're good. Cool. All right, so you already added the book to your own website previously. Uh, and what I really like, and this one is not something necessarily that everybody can do, but I can, because I have Autumn. So if you have your own version of Autumn out there that you can do this too but, but it's really a nice, if you could put at this point in time on your own website so the people can purchase directly from you here on the website. Jesper (46m 50s): Oh this is such a cool tip because it gets to be so excited. Cause I guess in a computer geek group gurus runs in my family, um, you get to sell the book directly to readers, get a hundred percent of the profit and for the people buying from you, they get to get it early and it's just like win-win. Everyone's winning. I think my only warning is do check with your state laws. You might need a business license if your selling on your own website. So a big tip there. Otherwise you, I just think it's so exciting. Jesper (47m 20s): You get, you're your own little book store and readers are getting in early and yes you might lose sales off of Amazon but readers are getting your Book early. So this was a good thing. But yes it is. And, and I think of course, unless you are enrolled in Kindle unlimited and Your on pre-order, then this is a no-go because then you are breaking the terms of service. But if you're not in Kindle unlimited or any exclusive exclusivity programs. So that was hard to say. But if you're not in any way, any such programs, then this is where I will then schedule an email already now to go out 10 days before the release date and here in that email tell you the email subscribers that you can get the Book already. Jesper (48m 3s): Now if you buy it directly from this link so then you can point out to them how it actually supports you as Autumn was just explaining because you don't have to give, it gave a cut of the royalties to sites like Amazon. So basically you're telling them, Hey, as a surprise, surprise so you can get the book already now 10 days before everybody else and you are going to help me out by making sure that I get all the royalties, which you're a reader should be interested in. Absolutely. So that's a win win. Yeah. Autumn (48m 33s): And it's, like I said, it's fun and it's not too much coating, but you definitely have to check it out. So that's all you have to do it. It can, especially in the first time through, it's a little bit to set up. So that's enough for you. You were five weeks out. Unless you have some spare time and you know you're you, you are closer, you get to Launch you, the more things are going to take your time and the more you want it you're going to get tired. So the more spare time, if you want to make some images, you know, start gathering stuff for a social media posts because you were one of the day you release the day before you release, your going to be willing to put up a whole bunch of different images, different quotes, different reviews as they come in. Autumn (49m 15s): You want to make sure you have all of that stuff together. So start, make, you know, make yourself an electronic file and just dump images and ideas and stuff into it so that when you go to grab it, you have a whole bunch of stuff already there and you're not searching the web and getting frustrated because you just want to get it done now. Jesper (49m 32s): Yeah. Yes. Yeah. So let's move on. Four weeks ahead of launch soon, a month out now. And uh, well this is basically where you can fall once you do your future self a favor. Cause normally it happens so that your past self is an asshole is not right. It's true. Yeah because isn't it a soda? Your past self is always the one who's thinking, yeah, yeah I can do that later. Then your future self is like, Oh why the hell did not take care of this? Jesper (50m 6s): That's how it always worked. Right? So now you can flip that around and make you make your future self happy about the past self. And that's right. So schedule in an email again. Now two, go out to your email list. Seven days before the release date. And here you are going to tell them about that exclusive bonus that we just created. And your also going to tell them that this amazing book is available for preorder. Excellent. That's always useful. Jesper (50m 36s): And again this is, you still want to make sure you're posting about your book out on social media. And again you don't get things organized to get things together, get quotes together as well. Just make sure you have a whole bunch of stuff to share so that you have it all ready at your fingertips so that you are your future self is so happy with you having it was a good way to put it, your organized because it's so much easier than trying to look for passages. Um, during release week you want to sit there and celebrate really a sweet Necco. Jesper (51m 11s): I need to come up with 20 posts today in India. And to clarify, so you, you created the bonus itself six weeks ahead of launch and now we are at four weeks ahead of launch and I'm telling you to schedule an email only seven days before on. So basically why was it that we didn't just email people six weeks ahead of launch as soon as we create the exclusive post, and this is basically the reason for the that we don't email them is that we want to narrow the time window where they actually have the ability to get their hands on this bonus because the way people work and the way this goes and it is every single time without a fault, it is everybody only do what they need to do in the last second before the deadline expires. Jesper (51m 58s): And that's just the way it is. It is. If you don't believe me, fine. But that's the way it is. If you don't leave us alone, go on to our Facebook groups and find the four horseman of procrastination. Yes. And so that's why you are only giving them a seven day window and you are saying by the end of this week this is going to go away and a puff of smoke, it's going to be gone forever so they have to take action. Now. It's not like if you email them and say, well sometimes within the next six weeks you need to look at this, they will forget about and not do it. Jesper (52m 29s): So that's why that's very, okay. All right, so we're on two to three weeks. Three weeks now? Yes. All right, so that was a good time. You should be getting back, uh, messages from your arc team. Uh, if there were looking, hopefully again, and hopefully they were not doing content edits because that should have been beta reader is probably six months ago. So hopefully there's just some typos. There's going to be, typo is, trust me, there's always typos. You want to make sure that you have gathered those, you fix them and you don't upload every time someone gives you a type out, don't upload at the final version, save the, fix them all and a draft so that as you get closer, I think, what does that, Amazon's, what, three days? Jesper (53m 9s): You can't upload anything prior to Launch. So when you were in that window right now, you still have three weeks. Keep gathering. Um, but make sure that you're fixing them on a master a manuscript so that you will be ready to upload it once you have all of them back. Yeah. Amen. That's it. Yeah. So once you have all the information back, are you up to update your files and upload the final version once you are ready? All right, so we can move to two weeks ahead of Launch. So this is where I really like to start collecting keywords for the future Amazon ads that are going to run towards this book. Jesper (53m 44s): So basically start building up the list of keywords. Sounds good. And I will prefer tool For this is Publisher Rocket Yes that's an amazing piece of software and a way back when in episode 11 and matching that, that's a long time ago. But back then I talked about Publisher Rocket in that episode and then again in episode 32 we have Dave Chesson, he's the creator of Publisher Rocket. We had him on to talk about what you can do with Publisher Rocket and is one of my favorite tools. Jesper (54m 16s): So we will include a link to Publisher Rocket in the show notes so you can check it out. And if you want, we don't, you know, affiliate, we don't, we're not even an affiliate with him but we don't push to me as well. Oh I forgot about that. All right, so we asked, we are, you know these things more than you keep it organized, but as we don't feel to share too many tools. This is a really great one, but Publisher rocket is a really great one. And I will also say a huge shutout shout out. It's not that I think he listens to our show, but Brian Cohen, I just took his five day AMS edge challenge and it was a ton of fun and I learned stuff and he made some great tips for finding keywords and categories and stuff as well. Jesper (54m 56s): And he also mentioned publishers Rocket so those are a fun things. If you a join up with one of his challenges, you'll learn some great tips for getting more keywords as well. Yeah. Okay. One week ahead of Launch. Oh, are we getting to know? Yeah. So this is where I'll send another email to our list. And again, the purpose of this email is to build anticipation. Umm, so this could be the time where you and are using it as an extract of the actual book. Jesper (55m 28s): Perhaps you could also email the entire first chapter to people with a to be continued at the end of it. Um, and once again, yes, you guessed it, don't forget to include links to the preorder. Absolutely. I always, I do this for my readers. I especially cause a, you know, I'm Writing at least 40 chapter books. I will give away the first three chapters with links at the end of even the three chapters of where to go get a preorder and I get that to all my reader's on my mailing list. Yes. And now that you were inside, you are emailing software and doing email's anyway. Jesper (56m 2s): Then schedule and email as well to go out to your list at 6:00 AM am on launch day with the details about the book and all of the purchase links as well. Excellent. That's getting close. And so definitely at this point it's probably looking at where at one week Launch so you, you should have your final manuscript up Autumn (56m 24s): and ready to upload your final version two, the channel's because if you wait to close to launch it again, that three day window for Amazon. After that you can't touch her Book file. If you have it uploaded your for a final version, guess what? They are going to get the not final version. So get yourself a few days at a deep breath and get your final book up there. Yeah, hopefully you're already done it by now, but at least at this point it's just the latest yet. This is what you need. The original definition have a deadline is a lion. Autumn (56m 55s): You deduct CROs on pain of death. Am this is your deadline and get your book up there. Jesper (57m 0s): Yeah. Okay. So we are heading into the final stretch here at a three days ahead of Launch. Uh, there is only a few things that I do here. So basically logging into Amazon author central to basically claim your book there. So there is a co, a tab in author central called Book top and you click on add more books there, find your niche, search for your name, find a book that you're publishing and click at it and then it will be visible on your author page on, on Amazon. So I'll do that. And, and the same thing if you have a book or a profile or a profile on a BookBub, then you go there and claim the book there as well. Jesper (57m 36s): Yeah. And if you don't have it by now, make sure that you have good reads. Yes, yes, yes. And with BookBub AM do update all the Stallings on on your profile because that will automatically trick a book bub to send out and a new release alerts to your BookBub followers, which is, there is no reason not to do that. Autumn (57m 56s): That's very true. All right, we're really close to Launch. So right before she out, don't forget, this is where you're going to check for reviews. You're going to make sure, make sure that you just create a reminder. So you go in and you're going to check for some reviews coming up so that you can look for them. Oh, you're going to actually use the good ones, the five star Wars and stuff. You wanna use those for two year tips. But I know you have some tips, don't you? For if you get any bad reviews, right? Jesper (58m 29s): Well yeah well that the TEP is basically to make sure that you check that the bad reviews is within terms of service. So if somebody starts complaining about things that are not with in terms of service, which to be honest, we are going to cover a much more in the free cost. So maybe that's too much detailed to go in to hear. But make a long story short just to say that there are ways in which you can get Amazon to remove a bad review. Um, but I think there are all the details of that is not really related to launching. Jesper (59m 0s): So maybe we can come back to that and in the free course I am going to explain it in detail there. Sounds good. Yeah. So all I will do here one day ahead of launch is just to send out an email to your list to say, Hey, it's coming tomorrow. Uh, and remind them as well that this is now the last chance to get that exclusive preorder a bonus. Excellent. It's Scott, that's a good tip. And this is probably the place where you are going to get most people. Autumn (59m 27s): This is pretty and there always wait for the last bit. Yes. Um, but then so that's Launch exciting. All right. First are you going to wake up and you're going to toast yourself with a mimosa to celebrate? Don't forget to celebrate. This is a big, big day. No matter how many books you launch, it's always exciting to lunch a book. So, but also hopefully you already had a schedule, but you know, email your launch team because this is your arc team. This was the reason you gave away all those free copies. Autumn (59m 59s): It was helpful to get the typos. Admittedly, they have saved my butt on more than one occasion, including the very careful reader who's did you mean this guy and not that one can. I can I tell you that Jesper (1h 0m 10s): by the way, that it was once as well as the one of the arc team members came back to me and said, so why is half of this chapter in this book twice? Oh no. And I went and apparently once I got the edited version back from the editor, for some reason I, I can't remember what I have been doing, but I have been copying, pasting stuff for some reason and I forgot to delete my old original first draft version. So it had my first draft version of half of the chapter in there together with the editors. Jesper (1h 0m 42s): Correct it. Luckily this person capture recorded and told me about it so I could delete it. But it was like Jesus. I mean if I hadn't, if the act team hadn't told me, I wouldn't have noticed. Autumn (1h 0m 55s): Yeah. Uh, you know how your arch team members, they are lifesavers but the whole of the reason that they're really there and the reason you recruit them in the reason you vet them as well, which is important, you shouldn't just let everyone in it, especially if you've written a few books, is because on today the day you Book Launch you tell them, Hey, it's time for you to do your job and say thank you and leave a review. That's that sort of what the whole deal was. Autumn (1h 1m 26s): They get to leave an honest review. That's the important key. You're not asking them for a good review or a bad review. It's Jesper (1h 1m 33s): an honest, right. There is even more important key here because you need, this is where you need to be really careful and you also have to be careful how you are a word in your email because according to Amazon's, again in terms of service, you cannot give out an ad copy and demand a review in return. So the only thing you can do when you are wearing your email here is that you can appreciate it. Tell them how much you would appreciate it. If they would want to leave an honest review on a book, then it would really mean a lot to you and then you can of course explain how reviews means a lot to the success of a book and explain why it is important because most people actually even know we are authors. Jesper (1h 2m 14s): We know why it's important, but a lot of readers don't. So you explain that to them and you can kindly ask them that. It would be really nice if they would want to do it, but you cannot say, I gave you an art copy. Now you need to give me a review. Because you knew that when you were breaking the terms of service. Absolutely. A very good tip because you don't wanna piss off of Amazon. No, no. It's weird. Most of the book sales come from so be nice to Amazon, follow their rules and Yes. Jesper (1h 2m 44s): The reason you got an arc team together was hopefully to get, you know, if you had a hundred member team, if you get over 50 as you can get like 75 reviews, that's been stick a while. That's a little bit, but again, most the time, you know a year not going to get a hundred percent of people leaving reviews. Some people are going to be busy and they're not all gonna happen on the first day. I've most of the time, if they come within the first week, that's, that's great. Yeah. We again, we are going to talk more about this in the, in the free course. So now that's basically all you need to do on launch day. Jesper (1h 3m 16s): So thankfully, thankfully, because we've been doing so much work ahead of monsters, so much to do now it's everything has been set up and everything is running. So that's nice. And then one day after launch I would just go in and start activating Amazon ads and if you want to do Facebook ads then this is also at the time where I would get those going. But that's basically it. And if you did do a preorder sale price, you know, you have to think about how many days you want to leave that going. But you might have some people change it after one day. Jesper (1h 3m 47s): Some people leave it up for a week. But if you had a preorder, um, a special discount. Yeah. The book's live now that you might wanna think about changing that. Yeah. And of course that exclusive launch bonus

Listen to the CEO who is setting the example of how to scale a business while making it even more sustainable. You'll get energized to want to improve your business, your meetings and things you don't think possible.

Born from the fires of the industrial revolution, this candy has been described as disgusting, old, weird, chalky. the candy that can sit on the shelf for years and not lose an iota of flavor, the Necco Wafer. Learn more at A Brief History in Candy --- Send in a voice message: https://anchor.fm/briefhistorycandy/message

News That Didn't Make the News: Necco wafters are going away and what to do if you have a gambling problem.

PLUS: Colleen and Bradley Theatre: Kris and Kim Krisis Kontrol. Necco wafers may go extinct. AND day three of audition week on Throwback Live at 1:45.

The ASMR talk show hosted by Adam Papagan. This week, storyteller Scott Schultz discusses the Salem Witch Trials, bus scars, and his favorite Necco wafers. Watch Wednesdays 10:05PM pst at Dromebox.com Subscribe on YouTube: https://www.youtube.com/channel/UC5ai92I1SvymJ9Urg08CDeQ adampapagan@gmail.com